A Multicenter Longitudinal MRI Study Assessing LeMan-PV Software Accuracy in the Detection of White Matter Lesions in Multiple Sclerosis Patients
Todea A.R.; Melie-Garcia L.; Barakovic M.; Cagol A.; Rahmanzadeh R.; Galbusera R.; Lu P.-J.; Weigel M.; Ruberte E.; Radue E.-W.; Schaedelin S.; Benkert P.; Oezguer Y.; Sinnecker T.; Muller S.; Achtnichts L.; Vehoff J.; Disanto G.; Findling O.; Chan A.; Salmen A.; Pot C.; Lalive P.; Bridel C.; Zecca C.; Derfuss T.; Remonda L.; Wagner F.; Vargas M.; Du Pasquier R.; Pravata E.; Weber J.; Gobbi C.; Leppert D.; Wuerfel J.; Kober T.; Marechal B.; Corredor-Jerez R.; Psychogios M.; Lieb J.; Kappos L.; Cuadra M.B.; Kuhle J.; Granziera C.. Journal of Magnetic Resonance Imaging. 2023.Anterior horn atrophy in the cervical spinal cord: A new biomarker in progressive multiple sclerosis.
Tsagkas C; Huck-Horvath A; Cagol A; Haas T; Barakovic M; Amann M; Ruberte E; Melie-Garcia L; Weigel M; Pezold S; Schlaeger R; Kuhle J; Sprenger T; Kappos L; Bieri O; Cattin P; Granziera C; Parmar K. Multiple sclerosis (Houndmills, Basingstoke, England). 2023.Assessing the commutability of candidate reference materials for the harmonization of neurofilament light measurements in blood.
Andreasson U; Gobom J; Delatour V; Auclair G; Noam Y; Lee S; Wen J; Jeromin A; Arslan B; Maceski A; Willemse E; Zetterberg H; Kuhle J; Blennow K. Clinical chemistry and laboratory medicine. 2023.Comparative effectiveness of cladribine tablets versus other oral disease-modifying treatments for multiple sclerosis: Results from MSBase registry.
Spelman T; Ozakbas S; Alroughani R; Terzi M; Hodgkinson S; Laureys G; Kalincik T; Van Der Walt A; Yamout B; Lechner-Scott J; Soysal A; Kuhle J; Sanchez-Menoyo JL; Blanco Morgado Y; Spitaleri D; van Pesch V; Horakova D; Ampapa R; Patti F; Macdonell R; Al-Asmi A; Gerlach O; Oh J; Altintas A; Tundia N; Wong SL; Butzkueven H. Multiple sclerosis (Houndmills, Basingstoke, England). 2023.Correlation of disability with quality of life in patients with multiple sclerosis treated with natalizumab: primary results and post hoc analysis of the TYSabri ImPROvement study (PROTYS).
Achtnichts L; Zecca C; Findling O; Kamm CP; Mueller S; Kuhle J; Lutterotti A; Gobbi C; Viviani C; Villiger-Borter E; Nedeltchev K. BMJ neurology open. 2023.Evaluation of frequency, severity, and independent risk factors for recurrence of disease activity after fingolimod discontinuation in a large real-world cohort of patients with multiple sclerosis
Cerda-Fuertes N.; Nagy S.; Schaedelin S.; Sinnecker T.; Ruberte E.; Papadopoulou A.; Wurfel J.; Kuhle J.; Yaldizli O.; Kappos L.; Derfuss T.; Decard B.F.. Therapeutic advances in neurological disorders. 2023.High serum neurofilament light chain levels correlate with brain atrophy and physical disability in multiple sclerosis.
Buchmann A; Pirpamer L; Pinter D; Voortman M; Helmlinger B; Pichler A; Maceski AM; Benkert P; Bachmaier G; Ropele S; Reindl M; Leppert D; Kuhle J; Enzinger C; Khalil M. European Journal of Neurology. 2023.Longitudinal assessment of cervical spinal cord compartments in multiple sclerosis.
Tsagkas C; Huck-Horvath A; Cagol A; Haas T; Amann M; Barakovic M; Ruberte E; Melie-Garcia L; Weigel M; Pezold S; Schlaeger R; Kuhle J; Sprenger T; Kappos L; Bieri O; Cattin P; Granziera C; Parmar K. Multiple Sclerosis and Related Disorders. 2023.Natalizumab in cerebrospinal fluid and breastmilk of patients with multiple sclerosis.
Callegari I; Schneider M; Aebischer V; Voortman MM; Proschmann U; Ziemssen T; Lindberg R; Fischer-Barnicol B; Khalil M; Kappos L; Kuhle J; Sanderson NSR; Derfuss T. Therapeutic advances in neurological disorders. 2023.Neurofilament light (NfL) as biomarker in serum and CSF in status epilepticus.
Margraf NG; Dargvainiene J; Theel E; Leypoldt F; Lieb W; Franke A; Berger K; Kuhle J; Kuhlenbaeumer G. Journal of Neurology. 2023.Optical coherence tomography reflects clinically relevant gray matter damage in patients with multiple sclerosis.
Cagol A; Fuertes NC; Stoessel M; Barakovic M; Schaedelin S; D'Souza M; Würfel J; Brandt AU; Kappos L; Sprenger T; Naegelin Y; Kuhle J; Granziera C; Papadopoulou A. Journal of Neurology. 2023.Plasma neurofilament light chain in children with relapsing MS receiving teriflunomide or placebo: A post hoc analysis of the randomized TERIKIDS trial
Kuhle J.; Chitnis T.; Banwell B.; Tardieu M.; Arnold D.L.; Rawlings A.M.; Geertsen S.S.; Lublin A.L.; Saubadu S.; Truffinet P.; Kappos L.. Multiple sclerosis (Houndmills, Basingstoke, England). 2023.Real-world evaluation of ocrelizumab in multiple sclerosis: A systematic review.
Montalban X; Matthews PM; Simpson A; Petrie JL; Sammon C; Ramagopalan S; Disanto G; Kuhle J. Annals of Clinical and Translational Neurology. 2023.Serum Glial Fibrillary Acidic Protein Compared With Neurofilament Light Chain as a Biomarker for Disease Progression in Multiple Sclerosis
Meier S.; Willemse E.A.J.; Schaedelin S.; Oechtering J.; Lorscheider J.; Melie-Garcia L.; Cagol A.; Barakovic M.; Galbusera R.; Subramaniam S.; Barro C.; Abdelhak A.; Thebault S.; Achtnichts L.; Lalive P.; Muller S.; Pot C.; Salmen A.; Disanto G.; Zecca C.; D'souza M.; Orleth A.; Khalil M.; Buchmann A.; Du Pasquier R.; Yaldizli O.; Derfuss T.; Berger K.; Hermesdorf M.; Wiendl H.; Piehl F.; Battaglini M.; Fischer U.; Kappos L.; Gobbi C.; Granziera C.; Bridel C.; Leppert D.; Maleska Maceski A.; Benkert P.; Kuhle J.. JAMA neurology. 2023.Serum neurofilament light chain as a reliable biomarker of hereditary transthyretin-related amyloidosis-A Swiss reference center experience.
Loser V; Benkert P; Vicino A; Lim Dubois Ferriere P; Kuntzer T; Pasquier J; Maceski A; Kuhle J; Theaudin M. . 2023.Serum neurofilament light chain in functionally relevant coronary artery disease and adverse cardiovascular outcomes.
Amrein M; Meier S; Schäfer I; Schaedelin S; Willemse E; Benkert P; Walter J; Puelacher C; Zimmermann T; Median D; Egli C; Leppert D; Twerenbold R; Zellweger M; Kuhle J; Mueller C. Biomarkers : biochemical indicators of exposure, response, and susceptibility to chemicals. 2023.Synthesizing cross-design evidence and cross-format data using network meta-regression.
Hamza T; Chalkou K; Pellegrini F; Kuhle J; Benkert P; Lorscheider J; Zecca C; Iglesias-Urrutia CP; Manca A; Furukawa TA; Cipriani A; Salanti G. Research synthesis methods. 2023.The multifaceted role of neurofilament light chain protein in non-primary neurological diseases.
Abu-Rumeileh S; Abdelhak A; Foschi M; D'Anna L; Russo M; Steinacker P; Kuhle J; Tumani H; Blennow K; Otto M. Brain. 2023.The role of neurofilament light in genetic frontotemporal lobar degeneration.
Zetterberg H; Teunissen C; van Swieten J; Kuhle J; Boxer A; Rohrer JD; Mitic L; Nicholson AM; Pearlman R; McCaughey SM; Tatton N. Brain communications. 2023.A comparative assessment of myelin-sensitive measures in multiple sclerosis patients and healthy subjects.
Rahmanzadeh R; Weigel M; Lu PJ; Melie-Garcia L; Nguyen TD; Cagol A; La Rosa F; Barakovic M; Lutti A; Wang Y; Bach Cuadra M; Radue EW; Gaetano L; Kappos L; Kuhle J; Magon S; Granziera C. NeuroImage. Clinical. 2022.Age-Adjusted Serum Neurofilament Predicts Cognitive Decline in Parkinson's Disease (MARK-PD)
Buhmann C.; Lezius S.; Potter-Nerger M.; Gerloff C.; Kuhle J.; Choe C.-U.. Movement Disorders. 2022.Age-dependent gray matter demyelination is associated with leptomeningeal neutrophil accumulation.
Zuo M; Fettig NM; Bernier LP; Pössnecker E; Spring S; Pu A; Ma XI; Lee DS; Ward LA; Sharma A; Kuhle J; Sled JG; Pröbstel AK; MacVicar BA; Osborne LC; Gommerman JL; Ramaglia V. JCI Insight. 2022.A Method to Combine Neurofilament Light Measurements From Blood Serum and Plasma in Clinical and Population-Based Studies
Rubsamen N.; Willemse E.A.J.; Leppert D.; Wiendl H.; Nauck M.; Karch A.; Kuhle J.; Berger K.. Frontiers in Neurology. 2022.A New Advanced MRI Biomarker for Remyelinated Lesions in Multiple Sclerosis.
Rahmanzadeh R; Galbusera R; Lu PJ; Bahn E; Weigel M; Barakovic M; Franz J; Nguyen TD; Spincemaille P; Schiavi S; Daducci A; La Rosa F; Absinta M; Sati P; Bach Cuadra M; Radue EW; Leppert D; Kuhle J; Kappos L; Brück W; Reich DS; Stadelmann C; Wang Y; Granziera C. Annals of Neurology. 2022.Association of age and disease duration with comorbidities and disability: A study of the Swiss Multiple Sclerosis Registry.
Stanikić M; Salmen A; Chan A; Kuhle J; Kaufmann M; Ammann S; Schafroth S; Rodgers S; Haag C; Pot C; Kamm CP; Zecca C; Gobbi C; Calabrese P; Manjaly ZM; von Wyl V; Swiss Multiple Sclerosis Registry (SMSR). Multiple Sclerosis and Related Disorders. 2022.Association of Brain Atrophy With Disease Progression Independent of Relapse Activity in Patients With Relapsing Multiple Sclerosis.
Cagol A; Schaedelin S; Barakovic M; Benkert P; Todea RA; Rahmanzadeh R; Galbusera R; Lu PJ; Weigel M; Melie-Garcia L; Ruberte E; Siebenborn N; Battaglini M; Radue EW; Yaldizli Ö; Oechtering J; Sinnecker T; Lorscheider J; Fischer-Barnicol B; Müller S; Achtnichts L; Vehoff J; Disanto G; Findling O; Chan A; Salmen A; Pot C; Bridel C; Zecca C; Derfuss T; Lieb JM; Remonda L; Wagner F; Vargas MI; Du Pasquier R; Lalive PH; Pravatà E; Weber J; Cattin PC; Gobbi C; Leppert D; Kappos L; Kuhle J; Granziera C. JAMA neurology. 2022.Author Response: Blood Neurofilament Light in Progressive Multiple Sclerosis: Post Hoc Analysis of 2 Randomized Controlled Trials.
Leppert D; Kropshofer H; Häring D; Dahlke F; Patil A; Meinert R; Tomic D; Kappos L; Kuhle J. Neurology. 2022.Baseline Inflammatory Status Reveals Dichotomic Immune Mechanisms Involved In Primary-Progressive Multiple Sclerosis Pathology
Fernandez-Velasco J.I.; Monreal E.; Kuhle J.; Meca-Lallana V.; Meca-Lallana J.; Izquierdo G.; Oreja-Guevara C.; Gascon-Gimenez F.; Sainz de la Maza S.; Walo-Delgado P.E.; Lapuente-Suanzes P.; Maceski A.; Rodriguez-Martin E.; Roldan E.; Villarrubia N.; Saiz A.; Blanco Y.; Diaz-Perez C.; Valero-Lopez G.; Diaz-Diaz J.; Aladro Y.; Brieva L.; Iniguez C.; Gonzalez-Suarez I.; Rodriguez de Antonio L.A.; Garcia-Dominguez J.M.; Sabin J.; Llufriu S.; Masjuan J.; Costa-Frossard L.; Villar L.M.. Frontiers in immunology. 2022.Blood GFAP as an emerging biomarker in brain and spinal cord disorders
Abdelhak A.; Foschi M.; Abu-Rumeileh S.; Yue J.K.; D'Anna L.; Huss A.; Oeckl P.; Ludolph A.C.; Kuhle J.; Petzold A.; Manley G.T.; Green A.J.; Otto M.; Tumani H.. Nature reviews. Neurology. 2022.Blood Neurofilament Light in Progressive Multiple Sclerosis: Post Hoc Analysis of 2 Randomized Controlled Trials.
Leppert D; Kropshofer H; Häring DA; Dahlke F; Patil A; Meinert R; Tomic D; Kappos L; Kuhle J. Neurology. 2022.Brain atrophy measurement over a MRI scanner change in multiple sclerosis.
Sinnecker T; Schädelin S; Benkert P; Ruberte E; Amann M; Lieb JM; Naegelin Y; Müller J; Kuhle J; Derfuss T; Kappos L; Wuerfel J; Granziera C; Yaldizli Ö. NeuroImage. Clinical. 2022.Case Report: A 72-Year-Old Woman With Progressive Motor Weakness, Dry Eyes and High Levels of Serum Neurofilament Light Chain
Wendebourg M.J.; Kuhle J.; Hardmeier M.. Frontiers in Neurology. 2022.Changes in serum neurofilament light chain levels following narrowband ultraviolet B phototherapy in clinically isolated syndrome
Fabis-Pedrini M.J.; Kuhle J.; Roberts K.M.A.; Trend S.; Jones A.P.; Maceski A.; Carroll W.M.; Lucas R.M.; Mastaglia F.L.; Hart P.H.; Kermode A.G.. Brain and Behavior. 2022.Choroid Plexus Volume in Multiple Sclerosis vs Neuromyelitis Optica Spectrum Disorder: A Retrospective, Cross-sectional Analysis.
Müller J; Sinnecker T; Wendebourg MJ; Schläger R; Kuhle J; Schädelin S; Benkert P; Derfuss T; Cattin P; Jud C; Spiess F; Amann M; Lincke T; Barakovic M; Cagol A; Tsagkas C; Parmar K; Pröbstel AK; Reimann S; Asseyer S; Duchow A; Brandt A; Ruprecht K; Hadjikhani N; Fukumoto S; Watanabe M; Masaki K; Matsushita T; Isobe N; Kira JI; Kappos L; Würfel J; Granziera C; Paul F; Yaldizli Ö. Neurology(R) neuroimmunology & neuroinflammation. 2022.Comparing switch to ocrelizumab, cladribine or natalizumab after fingolimod treatment cessation in multiple sclerosis.
Zhu C; Zhou Z; Roos I; Merlo D; Kalincik T; Ozakbas S; Skibina O; Kuhle J; Hodgkinson S; Boz C; Alroughani R; Lechner-Scott J; Barnett M; Izquierdo G; Prat A; Horakova D; Kubala Havrdova E; Macdonell R; Patti F; Khoury SJ; Slee M; Karabudak R; Onofrj M; Van Pesch V; Prevost J; Monif M; Jokubaitis V; van der Walt A; Butzkueven H; MSBase Study Group. Journal of Neurology, Neurosurgery and Psychiatry. 2022.Corrigendum: Determination of CSF GFAP, CCN5, and vWF levels enhances the diagnostic accuracy of clinically defined MS from non-MS patients with CSF oligoclonal bands.
Probert F; Yeo T; Zhou Y; Sealey M; Arora S; Palace J; Claridge TDW; Hillenbrand R; Oechtering J; Kuhle J; Leppert D; Anthony DC. . 2022.Corrigendum to Longitudinal machine learning modeling of MS patient trajectories improves predictions of disability progression: [Computer Methods and Programs in Biomedicine, Volume 208, (September 2021) 106180].
De Brouwer E; Becker T; Moreau Y; Havrdova EK; Trojano M; Eichau S; Ozakbas S; Onofrj M; Grammond P; Kuhle J; Kappos L; Sola P; Cartechini E; Lechner-Scott J; Alroughani R; Gerlach O; Kalincik T; Granella F; Grand'Maison F; Bergamaschi R; Sá MJ; Van Wijmeersch B; Soysal A; Sanchez-Menoyo JL; Solaro C; Boz C; Iuliano G; Buzzard K; Aguera-Morales E; Terzi M; Trivio TC; Spitaleri D; Van Pesch V; Shaygannejad V; Moore F; Oreja-Guevara C; Maimone D; Gouider R; Csepany T; Ramo-Tello C; Peeters L. . 2022.CSF chitinase 3-like 1 is associated with iron rims in patients with a first demyelinating event.
Comabella M; Clarke MA; Schaedelin S; Tintoré M; Pareto D; Fissolo N; Pinteac R; Granziera C; Sastre-Garriga J; Benkert P; Auger C; Kuhle J; Montalban X; Rovira A. Multiple sclerosis (Houndmills, Basingstoke, England). 2022.Decreased neurofilament light chain levels in estriol-treated multiple sclerosis
Voskuhl R.; Kuhle J.; Siddarth P.; Itoh N.; Patel K.; MacKenzie-Graham A.. Annals of Clinical and Translational Neurology. 2022.Determination of CSF GFAP, CCN5, and vWF Levels Enhances the Diagnostic Accuracy of Clinically Defined MS From Non-MS Patients With CSF Oligoclonal Bands
Probert F.; Yeo T.; Zhou Y.; Sealey M.; Arora S.; Palace J.; Claridge T.D.W.; Hillenbrand R.; Oechtering J.; Kuhle J.; Leppert D.; Anthony D.C.. Frontiers in immunology. 2022.Development of an age-adjusted model for blood neurofilament light chain
Harp C.; Thanei G.-A.; Jia X.; Kuhle J.; Leppert D.; Schaedelin S.; Benkert P.; von Budingen H.-C.; Hendricks R.; Herman A.. Annals of Clinical and Translational Neurology. 2022.Diabetes, Glycated Hemoglobin (HbA1c), and Neuroaxonal Damage in Parkinson's Disease (MARK-PD Study)
Uyar M.; Lezius S.; Buhmann C.; Potter-Nerger M.; Schulz R.; Meier S.; Gerloff C.; Kuhle J.; Choe C.-U.. Movement Disorders. 2022.Dynamics of Inflammatory and Neurodegenerative Biomarkers after Autologous Hematopoietic Stem Cell Transplantation in Multiple Sclerosis
Ruder J.; Dinner G.; Maceski A.; Berenjeno-Correa E.; Muller A.M.; Jelcic I.; Kuhle J.; Martin R.. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES. 2022.GnRH replacement rescues cognition in Down syndrome
Manfredi-Lozano M.; Leysen V.; Adamo M.; Paiva I.; Rovera R.; Pignat J.-M.; Timzoura F.E.; Candlish M.; Eddarkaoui S.; Malone S.A.; Silva M.S.B.; Trova S.; Imbernon M.; Decoster L.; Cotellessa L.; Tena-Sempere M.; Claret M.; Paoloni-Giacobino A.; Plassard D.; Paccou E.; Vionnet N.; Acierno J.; Maceski A.M.; Lutti A.; Pfrieger F.; Rasika S.; Santoni F.; Boehm U.; Ciofi P.; Buee L.; Haddjeri N.; Boutillier A.-L.; Kuhle J.; Messina A.; Draganski B.; Giacobini P.; Pitteloud N.; Prevot V.. Science. 2022.Gut microbiota composition as a candidate risk factor for dimethyl fumarate-induced lymphopenia in multiple sclerosis.
Diebold M; Meola M; Purushothaman S; Siewert LK; Pössnecker E; Roloff T; Lindberg RL; Kuhle J; Kappos L; Derfuss T; Egli A; Pröbstel AK. Gut microbes. 2022.High-dimensional immune profiling identifies a biomarker to monitor dimethyl fumarate response in multiple sclerosis.
Diebold M; Galli E; Kopf A; Sanderson NSR; Callegari I; Benkert P; Gonzalo Núñez N; Ingelfinger F; Herms S; Cichon S; Kappos L; Kuhle J; Becher B; Claassen M; Derfuss T. Proceedings of the National Academy of Sciences of the United States of America. 2022.Immunological Predictors of Dimethyl Fumarate-Induced Lymphopenia.
Diebold M; Galli E; Kopf A; Sanderson N; Callegari I; Ingelfinger F; Núñez NG; Benkert P; Kappos L; Kuhle J; Becher B; Claassen M; Derfuss T. Annals of Neurology. 2022.Increased Neurofilament Light Chain Is Associated with Increased Risk of Long-Term Mortality in Cerebral Small Vessel Disease.
Jacob MA; Peters N; Cai M; Duering M; Engelter ST; Kuhle J; de Leeuw FE; Tuladhar AM. Journal of stroke. 2022.Intrathecal IgM Synthesis Is Associated with Spinal Cord Manifestation and Neuronal Injury in Early MS.
Oechtering J; Lincke T; Schaedelin S; Décard BF; Maceski A; Orleth A; Meier S; Willemse E; Buchmann A; Khalil M; Derfuss T; Benkert P; Heijnen I; Regeniter A; Müller S; Achtnichts L; Lalive P; Salmen A; Pot C; Gobbi C; Kappos L; Granziera C; Leppert D; Schlaeger R; Lieb JM; Kuhle J; Swiss MS Cohort Study. Annals of Neurology. 2022.Learn to Ignore: Domain Adaptation for Multi-site MRI Analysis
Wolleb J.; Sandkuhler R.; Bieder F.; Barakovic M.; Hadjikhani N.; Papadopoulou A.; Yaldizli O.; Kuhle J.; Granziera C.; Cattin P.C.. . 2022.Lifestyle factors in multiple sclerosis disability progression and silent brain damage: A cross-sectional study
Van Hijfte L.; Loret G.; Bachmann H.; Reynders T.; Breuls M.; Deschepper E.; Kuhle J.; Willekens B.; Laureys G.. Multiple Sclerosis and Related Disorders. 2022.Longitudinal analyses of serum neurofilament light and associations with obesity indices and bioelectrical impedance parameters
Hermesdorf M.; Leppert D.; Maceski A.; Benkert P.; Wellmann J.; Wiendl H.; Kuhle J.; Berger K.. Scientific Reports. 2022.Longitudinal analysis reveals high prevalence of Epstein-Barr virus associated with multiple sclerosis.
Bjornevik K; Cortese M; Healy BC; Kuhle J; Mina MJ; Leng Y; Elledge SJ; Niebuhr DW; Scher AI; Munger KL; Ascherio A. Science. 2022.Metabolomics detects clinically silent neuroinflammatory lesions earlier than neurofilament-light chain in a focal multiple sclerosis animal model
Yeo T.; Bayuangga H.; Augusto-Oliveira M.; Sealey M.; Claridge T.D.W.; Tanner R.; Leppert D.; Palace J.; Kuhle J.; Probert F.; Anthony D.C.. Journal of Neuroinflammation. 2022.Microstructure-Weighted Connectomics in Multiple Sclerosis.
Bosticardo S; Schiavi S; Schaedelin S; Lu PJ; Barakovic M; Weigel M; Kappos L; Kuhle J; Daducci A; Granziera C. Brain connectivity. 2022.Minocycline treatment in clinically isolated syndrome and serum NfL, GFAP, and metalloproteinase levels
Camara-Lemarroy C.; Metz L.; Kuhle J.; Leppert D.; Willemse E.; Li D.K.B.; Traboulsee A.; Greenfield J.; Cerchiaro G.; Silva C.; Yong V.W.. Multiple sclerosis (Houndmills, Basingstoke, England). 2022.Neuro-axonal injury in COVID-19: the role of systemic inflammation and SARS-CoV-2 specific immune response
Hirzel C.; Grandgirard D.; Surial B.; Wider M.F.; Leppert D.; Kuhle J.; Walti L.N.; Schefold J.C.; Spinetti T.; Suter-Riniker F.; Dijkman R.; Leib S.L.. Therapeutic advances in neurological disorders. 2022.Neurofilament light chain plasma levels are associated with area of brain damage in experimental cerebral malaria
Wai C.H.; Jin J.; Cyrklaff M.; Genoud C.; Funaya C.; Sattler J.; Maceski A.; Meier S.; Heiland S.; Lanzer M.; Frischknecht F.; Kuhle J.; Bendszus M.; Hoffmann A.. Scientific Reports. 2022.Neurofilament Light Chain serum levels after Hypoxia-Ischemia in a newborn piglet model.
Kyng KJ; Wellmann S; Lehnerer V; Hansen LH; Kuhle J; Henriksen TB. Frontiers in Pediatrics. 2022.Plasma neurofilament light chain levels suggest neuroaxonal stability following therapeutic remyelination in people with multiple sclerosis
Abdelhak A.; Cordano C.; Boscardin W.J.; Caverzasi E.; Kuhle J.; Chan B.; Gelfand J.M.; Yiu H.H.; Oertel F.C.; Beaudry-Richard A.; Condor Montes S.; Oksenberg J.R.; Lario Lago A.; Boxer A.; Rojas-Martinez J.C.; Elahi F.M.; Chan J.R.; Green A.J.. Journal of Neurology, Neurosurgery and Psychiatry. 2022.Plasma P-Tau181 for the Discrimination of Alzheimer’s Disease from Other Primary Dementing and/or Movement Disorders
Tzartos J.S.; Boufidou F.; Stergiou C.; Kuhle J.; Willemse E.; Palaiodimou L.; Tsantzali I.; Sideri E.; Bonakis A.; Giannopoulos S.; Voumvourakis K.I.; Tsivgoulis G.; Tzartos S.J.; Kapaki E.; Paraskevas G.P.. Biomolecules. 2022.Prediction of multiple sclerosis outcomes when switching to ocrelizumab.
Zhong M; van der Walt A; Stankovich J; Kalincik T; Buzzard K; Skibina O; Boz C; Hodgkinson S; Slee M; Lechner-Scott J; Macdonell R; Prevost J; Kuhle J; Laureys G; Van Hijfte L; Alroughani R; Kermode AG; Butler E; Barnett M; Eichau S; van Pesch V; Grammond P; McCombe P; Karabudak R; Duquette P; Girard M; Taylor B; Yeh W; Monif M; Gresle M; Butzkueven H; Jokubaitis VG. Multiple sclerosis (Houndmills, Basingstoke, England). 2022.Prognostic biomarkers in primary progressive multiple sclerosis: Validating and scrutinizing multimodal evoked potentials.
Hardmeier M; Schlaeger R; Lascano AM; Toffolet L; Schindler C; Gobbi C; Lalive P; Kuhle J; Kappos L; Fuhr P. Clinical neurophysiology : official journal of the International Federation of Clinical Neurophysiology. 2022.Prognostic Value of Serum Neurofilament Light Chain for Disease Activity and Worsening in Patients With Relapsing Multiple Sclerosis: Results From the Phase 3 ASCLEPIOS I and II Trials.
Ziemssen T; Arnold DL; Alvarez E; Cross AH; Willi R; Li B; Kukkaro P; Kropshofer H; Ramanathan K; Merschhemke M; Kieseier B; Su W; Häring DA; Hauser SL; Kappos L; Kuhle J. Frontiers in immunology. 2022.Reader Response: Serum Neurofilament Light Association With Progression in Natalizumab-Treated Patients With Relapsing-Remitting Multiple Sclerosis.
Kropshofer H; Häring DA; Kappos L; Leppert D; Kuhle J. . 2022.Receptor clustering and pathogenic complement activation in myasthenia gravis depend on synergy between antibodies with multiple subunit specificities.
Rose N; Holdermann S; Callegari I; Kim H; Fruh I; Kappos L; Kuhle J; Müller M; Sanderson NSR; Derfuss T. Acta neuropathologica. 2022.Renal Function and Body Mass Index Contribute to Serum Neurofilament Light Chain Levels in Elderly Patients With Atrial Fibrillation.
Polymeris AA; Helfenstein F; Benkert P; Aeschbacher S; Leppert D; Coslovsky M; Willemse E; Schaedelin S; Blum MR; Rodondi N; Reichlin T; Moschovitis G; Wuerfel J; De Marchis GM; Engelter ST; Lyrer PA; Conen D; Kühne M; Osswald S; Bonati LH; Kuhle J; Swiss-AF Investigators. Frontiers in neuroscience. 2022.Reply to: “Diabetes and Neuroaxonal Damage in Parkinson's Disease”
Buhmann C.; Potter-Nerger M.; Schulz R.; Gerloff C.; Kuhle J.; Choe C.-U.. Movement Disorders. 2022.Serum glial fibrillary acidic protein correlates with retinal structural damage in aquaporin-4 antibody positive neuromyelitis optica spectrum disorder
Lin T.-Y.; Schindler P.; Grittner U.; Oertel F.C.; Lu A.; Motamedi S.; Yadav S.K.; Duchow A.S.; Jarius S.; Kuhle J.; Benkert P.; Brandt A.U.; Bellmann-Strobl J.; Schmitz-Hubsch T.; Paul F.; Ruprecht K.; Zimmermann H.G.. Multiple Sclerosis and Related Disorders. 2022.Serum Neurofilament Light Chain and Glial Fibrillary Acidic Protein as Biomarkers in Primary Progressive Multiple Sclerosis and Hereditary Spastic Paraplegia Type 4.
Kessler C; Ruschil C; Abdelhak A; Wilke C; Maleska A; Kuhle J; Krumbholz M; Kowarik MC; Schüle R. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES. 2022.Serum neurofilament light chain and postural instability/gait difficulty (PIGD) subtypes of Parkinson’s disease in the MARK-PD study
Potter-Nerger M.; Dutke J.; Lezius S.; Buhmann C.; Schulz R.; Gerloff C.; Kuhle J.; Choe C.-U.. Journal of Neural Transmission. 2022.Serum neurofilament light chain for individual prognostication of disease activity in people with multiple sclerosis: a retrospective modelling and validation study.
Benkert P; Meier S; Schaedelin S; Manouchehrinia A; Yaldizli Ö; Maceski A; Oechtering J; Achtnichts L; Conen D; Derfuss T; Lalive PH; Mueller C; Müller S; Naegelin Y; Oksenberg JR; Pot C; Salmen A; Willemse E; Kockum I; Blennow K; Zetterberg H; Gobbi C; Kappos L; Wiendl H; Berger K; Sormani MP; Granziera C; Piehl F; Leppert D; Kuhle J; NfL Reference Database in the Swiss Multiple Sclerosis Cohort Study Group. The Lancet Neurology. 2022.Serum NfL levels in the first five years predict 10-year thalamic fraction in patients with MS
Lokhande H.; Rosso M.; Tauhid S.; Chu R.; Healy B.C.; Saxena S.; Barro C.; Paul A.; Polgar-Turcsanyi M.; Anderson M.; Glanz B.I.; Kropshofer H.; Granziera C.; Leppert D.; Kappos L.; Kuhle J.; Weiner H.L.; Bakshi R.; Chitnis T.. Multiple sclerosis journal - experimental, translational and clinical. 2022.Severe Neuro-COVID is associated with peripheral immune signatures, autoimmunity and neurodegeneration: a prospective cross-sectional study.
Etter MM; Martins TA; Kulsvehagen L; Pössnecker E; Duchemin W; Hogan S; Sanabria-Diaz G; Müller J; Chiappini A; Rychen J; Eberhard N; Guzman R; Mariani L; Melie-Garcia L; Keller E; Jelcic I; Pargger H; Siegemund M; Kuhle J; Oechtering J; Eich C; Tzankov A; Matter MS; Uzun S; Yaldizli Ö; Lieb JM; Psychogios MN; Leuzinger K; Hirsch HH; Granziera C; Pröbstel AK; Hutter G. Nature Communications. 2022.Stratifying the Presymptomatic Phase of Genetic Frontotemporal Dementia by Serum NfL and pNfH: A Longitudinal Multicentre Study.
Wilke C; Reich S; van Swieten JC; Borroni B; Sanchez-Valle R; Moreno F; Laforce R; Graff C; Galimberti D; Rowe JB; Masellis M; Tartaglia MC; Finger E; Vandenberghe R; de Mendonça A; Tagliavini F; Santana I; Ducharme S; Butler CR; Gerhard A; Levin J; Danek A; Otto M; Frisoni G; Ghidoni R; Sorbi S; Bocchetta M; Todd E; Kuhle J; Barro C; Genetic Frontotemporal dementia Initiative (GENFI); Rohrer JD; Synofzik M. Annals of Neurology. 2022.Sustained reduction of serum neurofilament light chain over 7 years by alemtuzumab in early relapsing-remitting MS.
Kuhle J; Daizadeh N; Benkert P; Maceski A; Barro C; Michalak Z; Sormani MP; Godin J; Shankara S; Samad TA; Jacobs A; Chung L; Rӧsch N; Kaiser C; Mitchell CP; Leppert D; Havari E; Kappos L. Multiple sclerosis (Houndmills, Basingstoke, England). 2022.The CCR5 antagonist maraviroc exerts limited neuroprotection without improving neurofunctional outcome in experimental pneumococcal meningitis
Le N.D.; Steinfort M.; Grandgirard D.; Maleska A.; Leppert D.; Kuhle J.; Leib S.L.. Scientific Reports. 2022.Vaginal Delivery Is Associated with Neurochemical Evidence of Increased Neuroaxonal Remodelling in Infants from the KUNO-Kids Health Study: Cross-Sectional Analysis.
Kürner K; Goeral K; Atkinson A; Brandstetter S; Toncheva AA; Kabesch M; Apfelbacher C; Melter M; Seelbach-Göbel B; Berger A; Kuhle J; Wellmann S; KUNO-Kids study group. Neonatology. 2022.Altered neuroaxonal integrity in schizophrenia and major depressive disorder assessed with neurofilament light chain in serum.
Bavato F; Cathomas F; Klaus F; Gütter K; Barro C; Maceski A; Seifritz E; Kuhle J; Kaiser S; Quednow BB. Journal of psychiatric research. 2021.Antibodies to neurofilament light as potential biomarkers in multiple sclerosis.
Puentes F; Benkert P; Amor S; Kuhle J; Giovannoni G. BMJ neurology open. 2021.Biomarkers of treatment response in patients with progressive multiple sclerosis treated with high-dose pharmaceutical-grade biotin (MD1003).
Collongues N; Kuhle J; Tsagkas C; Lamy J; Meyer N; Barro C; Parmar K; Amann M; Wuerfel J; Kappos L; Moreau T; de Seze J. Brain and Behavior. 2021.Central nervous system atrophy predicts future dynamics of disability progression in a real-world multiple sclerosis cohort.
Tsagkas C; Naegelin Y; Amann M; Papadopoulou A; Barro C; Chakravarty MM; Gaetano L; Wuerfel J; Kappos L; Kuhle J; Granziera C; Sprenger T; Magon S; Parmar K. European Journal of Neurology. 2021.Characteristics of improvements in balance control using vibro-tactile biofeedback of trunk sway for multiple sclerosis patients.
Allum JHJ; Rust HM; Lutz N; Schouenborg C; Fischer-Barnicol B; Haller V; Derfuss T; Kuhle J; Yaldizli Ö. Journal of the neurological sciences. 2021.Chitotriosidase as biomarker for early stage amyotrophic lateral sclerosis: a multicenter study.
Steinacker P; Feneberg E; Halbgebauer S; Witzel S; Verde F; Oeckl P; Van Damme P; Gaur N; Gray E; Grosskreutz J; Jardel CG; Kachanov M; Kuhle J; Lamari F; Maceski A; Del Mar Amador M; Mayer B; Morelli C; Petri S; Poesen K; Raaphorst J; Salachas F; Silani V; Turner MR; Verbeek MM; Volk AE; Weishaupt JH; Weydt P; Ludolph AC; Otto M. Amyotrophic lateral sclerosis & frontotemporal degeneration. 2021.Chronic White Matter Inflammation and Serum Neurofilament Levels in Multiple Sclerosis.
Maggi P; Kuhle J; Schädelin S; van der Meer F; Weigel M; Galbusera R; Mathias A; Lu PJ; Rahmanzadeh R; Benkert P; La Rosa F; Bach Cuadra M; Sati P; Théaudin M; Pot C; van Pesch V; Leppert D; Stadelmann C; Kappos L; Du Pasquier R; Reich DS; Absinta M; Granziera C. Neurology. 2021.Classification of multiple sclerosis based on patterns of CNS regional atrophy covariance.
Tsagkas C; Parmar K; Pezold S; Barro C; Chakravarty MM; Gaetano L; Naegelin Y; Amann M; Papadopoulou A; Wuerfel J; Kappos L; Kuhle J; Sprenger T; Granziera C; Magon S. Human Brain Mapping. 2021.Combination of teriflunomide and interferon as follow-up therapy after fingolimod-associated PML
Fischer-Barnicol B.; Oechtering J.; Kuhle J.; Lorscheider J.; Kappos L.; Derfuss T.. Neurology(R) neuroimmunology & neuroinflammation. 2021.Comparative analysis of dimethyl fumarate and fingolimod in relapsing-remitting multiple sclerosis.
Lorscheider J; Benkert P; Lienert C; Hänni P; Derfuss T; Kuhle J; Kappos L; Yaldizli Ö. Journal of Neurology. 2021.Death Anxiety and Attitudes towards Death in Patients with Multiple Sclerosis: An Exploratory Study.
Francalancia J; Mavrogiorgou P; Juckel G; Mitrovic T; Kuhle J; Naegelin Y; Kappos L; Calabrese P. Brain sciences. 2021.De-escalating rituximab dose results in stability of clinical, radiological, and serum neurofilament levels in multiple sclerosis.
Disanto G; Ripellino P; Riccitelli GC; Sacco R; Scotti B; Fucili A; Pravatà E; Kuhle J; Gobbi C; Zecca C. Multiple sclerosis (Houndmills, Basingstoke, England). 2021.Development, validation and clinical usefulness of a prognostic model for relapse in relapsing-remitting multiple sclerosis.
Chalkou K; Steyerberg E; Bossuyt P; Subramaniam S; Benkert P; Kuhle J; Disanto G; Kappos L; Zecca C; Egger M; Salanti G. Diagnostic and prognostic research. 2021.Disability progression in relapse-free multiple sclerosis patients on fingolimod versus interferon-beta/glatiramer acetate.
von Wyl V; Benkert P; Moser A; Lorscheider J; Décard B; Hänni P; Lienert C; Kuhle J; Derfuss T; Kappos L; Yaldizli Ö. Multiple sclerosis (Houndmills, Basingstoke, England). 2021.Early life serum neurofilament dynamics predict neurodevelopmental outcome of preterm infants.
Goeral K; Hauck A; Atkinson A; Wagner MB; Pimpel B; Fuiko R; Klebermass-Schrehof K; Leppert D; Kuhle J; Berger A; Olischar M; Wellmann S. Journal of Neurology. 2021.Effect of Ocrelizumab in Blood Leukocytes of Patients With Primary Progressive MS.
Fernández-Velasco JI; Kuhle J; Monreal E; Meca-Lallana V; Meca-Lallana J; Izquierdo G; Gascón-Giménez F; Sainz de la Maza S; Walo-Delgado PE; Maceski A; Rodríguez-Martín E; Roldán E; Villarrubia N; Saiz A; Blanco Y; Sánchez P; Carreón-Guarnizo E; Aladro Y; Brieva L; Íñiguez C; González-Suárez I; Rodríguez de Antonio LA; Masjuan J; Costa-Frossard L; Villar LM. Neurology(R) neuroimmunology & neuroinflammation. 2021.Factors influencing serum neurofilament light chain levels in normal aging
Koini M.; Pirpamer L.; Hofer E.; Buchmann A.; Pinter D.; Ropele S.; Enzinger C.; Benkert P.; Leppert D.; Kuhle J.; Schmidt R.; Khalil M.. Aging. 2021.Fingolimod in children with Rett syndrome: the FINGORETT study.
Naegelin Y; Kuhle J; Schädelin S; Datta AN; Magon S; Amann M; Barro C; Ramelli GP; Heesom K; Barde YA; Weber P; Kappos L. Orphanet Journal of Rare Diseases. 2021.GAMER MRI: Gated-attention mechanism ranking of multi-contrast MRI in brain pathology.
Lu PJ; Yoo Y; Rahmanzadeh R; Galbusera R; Weigel M; Ceccaldi P; Nguyen TD; Spincemaille P; Wang Y; Daducci A; La Rosa F; Bach Cuadra M; Sandkühler R; Nael K; Doshi A; Fayad ZA; Kuhle J; Kappos L; Odry B; Cattin P; Gibson E; Granziera C. NeuroImage. Clinical. 2021.GAMER-MRI in Multiple Sclerosis Identifies the Diffusion-Based Microstructural Measures That Are Most Sensitive to Focal Damage: A Deep-Learning-Based Analysis and Clinico-Biological Validation.
Lu PJ; Barakovic M; Weigel M; Rahmanzadeh R; Galbusera R; Schiavi S; Daducci A; La Rosa F; Bach Cuadra M; Sandkühler R; Kuhle J; Kappos L; Cattin P; Granziera C. Frontiers in neuroscience. 2021.High serum neurofilament associates with diffuse white matter damage in MS.
Saraste M; Bezukladova S; Matilainen M; Tuisku J; Rissanen E; Sucksdorff M; Laaksonen S; Vuorimaa A; Kuhle J; Leppert D; Airas L. Neurology(R) neuroimmunology & neuroinflammation. 2021.Impact of complement activation on clinical outcomes in multiple sclerosis.
Keller CW; Oechtering J; Wiendl H; Kappos L; Kuhle J; Lünemann JD. Annals of Clinical and Translational Neurology. 2021.Increased serum glial fibrillary acidic protein associates with microstructural white matter damage in multiple sclerosis: GFAP and DTI.
Saraste M; Bezukladova S; Matilainen M; Sucksdorff M; Kuhle J; Leppert D; Airas L. Multiple Sclerosis and Related Disorders. 2021.Increased Serum Neurofilament Light and Thin Ganglion Cell-Inner Plexiform Layer Are Additive Risk Factors for Disease Activity in Early Multiple Sclerosis.
Lin TY; Vitkova V; Asseyer S; Martorell Serra I; Motamedi S; Chien C; Ditzhaus M; Papadopoulou A; Benkert P; Kuhle J; Bellmann-Strobl J; Ruprecht K; Paul F; Brandt AU; Zimmermann HG. Neurology(R) neuroimmunology & neuroinflammation. 2021.Increasing cancer risk over calendar year in people with multiple sclerosis: a case-control study.
Zecca C; Disanto G; Sacco R; MacLachlan S; Kuhle J; Ramagopalan SV; Gobbi C. Journal of Neurology. 2021.Integrative biochemical, proteomics and metabolomics cerebrospinal fluid biomarkers predict clinical conversion to multiple sclerosis.
Probert F; Yeo T; Zhou Y; Sealey M; Arora S; Palace J; Claridge TDW; Hillenbrand R; Oechtering J; Leppert D; Kuhle J; Anthony DC. Brain communications. 2021.Intrathecal Immunoglobulin M Synthesis is an Independent Biomarker for Higher Disease Activity and Severity in Multiple Sclerosis.
Oechtering J; Schaedelin S; Benkert P; Müller S; Achtnichts L; Vehoff J; Disanto G; Findling O; Fischer-Barnicol B; Orleth A; Chan A; Pot C; Barakovic M; Rahmanzadeh R; Galbusera R; Heijnen I; Lalive PH; Wuerfel J; Subramaniam S; Aeschbacher S; Conen D; Naegelin Y; Maceski A; Meier S; Berger K; Wiendl H; Lincke T; Lieb J; Yaldizli Ö; Sinnecker T; Derfuss T; Regeniter A; Zecca C; Gobbi C; Kappos L; Granziera C; Leppert D; Kuhle J; Swiss Multiple Sclerosis Cohort Study. Annals of Neurology. 2021.Longitudinal machine learning modeling of MS patient trajectories improves predictions of disability progression.
De Brouwer E; Becker T; Moreau Y; Havrdova EK; Trojano M; Eichau S; Ozakbas S; Onofrj M; Grammond P; Kuhle J; Kappos L; Sola P; Cartechini E; Lechner-Scott J; Alroughani R; Gerlach O; Kalincik T; Granella F; Grand'Maison F; Bergamaschi R; José Sá M; Van Wijmeersch B; Soysal A; Sanchez-Menoyo JL; Solaro C; Boz C; Iuliano G; Buzzard K; Aguera-Morales E; Terzi M; Trivio TC; Spitaleri D; Van Pesch V; Shaygannejad V; Moore F; Oreja-Guevara C; Maimone D; Gouider R; Csepany T; Ramo-Tello C; Peeters L. Computer Methods and Programs in Biomedicine. 2021.Major depressive disorder subtypes and depression symptoms in multiple sclerosis: What is different compared to the general population?
Rodgers S; Calabrese P; Ajdacic-Gross V; Steinemann N; Kaufmann M; Salmen A; Manjaly ZM; Kesselring J; Kamm CP; Kuhle J; Chan A; Gobbi C; Zecca C; Müller S; von Wyl V. Journal of Psychosomatic Research. 2021.Mass Cytometry of CSF Identifies an MS-Associated B-cell Population.
Johansson D; Rauld C; Roux J; Regairaz C; Galli E; Callegari I; Raad L; Waldt A; Cuttat R; Roma G; Diebold M; Becher B; Kuhle J; Derfuss T; Carballido JM; Sanderson NSR. Neurology(R) neuroimmunology & neuroinflammation. 2021.Measurement of neurofilaments improves stratification of future disease activity in early multiple sclerosis.
Uher T; Havrdova EK; Benkert P; Bergsland N; Krasensky J; Srpova B; Dwyer M; Tyblova M; Meier S; Vaneckova M; Horakova D; Zivadinov R; Leppert D; Kalincik T; Kuhle J. Multiple sclerosis (Houndmills, Basingstoke, England). 2021.MRI Lesion State Modulates the Relationship Between Serum Neurofilament Light and Age in Multiple Sclerosis.
Rosso M; Healy BC; Saxena S; Paul A; Bjornevik K; Kuhle J; Benkert P; Leppert D; Guttmann C; Bakshi R; Weiner HL; Chitnis T. Journal of neuroimaging : official journal of the American Society of Neuroimaging. 2021.Myelin and axon pathology in multiple sclerosis assessed by myelin water and multi-shell diffusion imaging.
Rahmanzadeh R; Lu PJ; Barakovic M; Weigel M; Maggi P; Nguyen TD; Schiavi S; Daducci A; La Rosa F; Schaedelin S; Absinta M; Reich DS; Sati P; Wang Y; Bach Cuadra M; Radue EW; Kuhle J; Kappos L; Granziera C. Brain. 2021.Neurofilament levels are associated with blood-brain barrier integrity, lymphocyte extravasation, and risk factors following the first demyelinating event in multiple sclerosis.
Uher T; McComb M; Galkin S; Srpova B; Oechtering J; Barro C; Tyblova M; Bergsland N; Krasensky J; Dwyer M; Havrdova EK; Posova H; Vaneckova M; Zivadinov R; Horakova D; Kuhle J; Ramanathan M. Multiple sclerosis (Houndmills, Basingstoke, England). 2021.Neurofilament light chain, a biomarker for polyneuropathy in systemic amyloidosis.
Louwsma J; Brunger AF; Bijzet J; Kroesen BJ; Roeloffzen WWH; Bischof A; Kuhle J; Drost G; Lange F; Kuks JBM; Gans ROB; Hazenberg BPC; Nienhuis HLA. Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis. 2021.Neurofilament light chain as a marker for cortical atrophy in multiple sclerosis without radiological signs of disease activity.
Ineichen BV; Moridi T; Ewing E; Ouellette R; Manouchehrinia A; Stawiarz L; Ferreira D; Muehlboeck SJ; Kuhle J; Westman E; Leppert D; Hillert J; Olsson T; Kockum I; Piehl F; Granberg T. . 2021.Neurofilament light chain in a phase 2 clinical trial of ibudilast in progressive multiple sclerosis.
Fox RJ; Raska P; Barro C; Karafa M; Konig V; Bermel RA; Chase M; Coffey CS; Goodman AD; Klawiter EC; Naismith RT; Kuhle J. Multiple sclerosis (Houndmills, Basingstoke, England). 2021.Neurofilament light chain predicts future dementia risk in cerebral small vessel disease.
Egle M; Loubiere L; Maceski A; Kuhle J; Peters N; Markus HS. Journal of Neurology, Neurosurgery and Psychiatry. 2021.Neurofilament results for the phase II neuroprotection study of phenytoin in optic neuritis.
Raftopoulos R; Kuhle J; Grant D; Hickman SJ; Altmann DR; Leppert D; Blennow K; Zetterberg H; Kapoor R; Giovannoni G; Gnanapavan S. European Journal of Neurology. 2021.Objective biomarkers for clinical relapse in multiple sclerosis: a metabolomics approach.
Yeo T; Probert F; Sealey M; Saldana L; Geraldes R; Höeckner S; Schiffer E; Claridge TDW; Leppert D; DeLuca G; Kuhle J; Palace J; Anthony DC. Brain communications. 2021.Prediagnostic Neurofilament Light Chain Levels in Amyotrophic Lateral Sclerosis.
Bjornevik K; O'Reilly EJ; Molsberry S; Kolonel LN; Le Marchand L; Paganoni S; Schwarzschild MA; Benkert P; Kuhle J; Ascherio A. Neurology. 2021.Predictive value of serum neurofilament light chain for persistent cognitive deficits in elderly depressive patients
Linnemann C.; Caviezel M.P.; Cramer L.; Melcher T.; Monsch A.U.; Kuhle J.; Leyhe T.. Journal of Affective Disorders Reports. 2021.Prognostic value of natural killer cell/T cell ratios for disease activity in multiple sclerosis.
Mimpen M; Muris AH; Rolf L; Gerlach O; Kuhle J; Hupperts R; Smolders J; Damoiseaux J. European Journal of Neurology. 2021.Quantification of the Neurofilament Light Chain Protein by Single Molecule Array (Simoa) Assay
Barro C.; Storz S.; Grobke S.; Michalak Z.; Kuhle J.. . 2021.Reply to: Neurofilament Light Chain in Patients with COVID-19 and Bacterial Pneumonia.
Leppert D; Sutter R; Kuhle J. . 2021.Serum GFAP and NfL as disease severity and prognostic biomarkers in patients with aquaporin-4 antibody-positive neuromyelitis optica spectrum disorder.
Schindler P; Grittner U; Oechtering J; Leppert D; Siebert N; Duchow AS; Oertel FC; Asseyer S; Kuchling J; Zimmermann HG; Brandt AU; Benkert P; Reindl M; Jarius S; Paul F; Bellmann-Strobl J; Kuhle J; Ruprecht K. Journal of Neuroinflammation. 2021.Serum neurofilament is associated with motor function, cognitive decline and subclinical cardiac damage in advanced Parkinson's disease (MARK-PD).
Niemann L; Lezius S; Maceski A; Leppert D; Englisch C; Schwedhelm E; Zeller T; Gerloff C; Kuhle J; Choe CU. Parkinsonism & related disorders. 2021.Serum neurofilament light and tau as prognostic markers for all-cause mortality in the elderly general population-an analysis from the MEMO study.
Rübsamen N; Maceski A; Leppert D; Benkert P; Kuhle J; Wiendl H; Peters A; Karch A; Berger K. BMC Medicine. 2021.Serum Neurofilament Light Chain: A Marker of Nervous System Damage in Myopathies
Saak A.; Benkert P.; Akgun K.; Willemse E.; Kuhle J.; Ziemssen T.; Jackson S.; Schaefer J.. Frontiers in Neuroscience. 2021.Serum neurofilament light chain (sNfL) values in a large cross-sectional population of children with asymptomatic to moderate COVID-19.
Geis T; Brandstetter S; Toncheva AA; Laub O; Leipold G; Wagner R; Kabesch M; Kasser S; Kuhle J; Wellmann S; CoKiBa Study group. Journal of Neurology. 2021.Serum neurofilament light chain as outcome marker for intensive care unit patients.
Fisse AL; Pitarokoili K; Leppert D; Motte J; Pedreiturria X; Kappos L; Gold R; Kuhle J; Yoon MS. Journal of Neurology. 2021.Serum Neurofilament Light Chain Levels in the Intensive Care Unit: Comparison between Severely Ill Patients with and without Coronavirus Disease 2019.
Sutter R; Hert L; De Marchis GM; Twerenbold R; Kappos L; Naegelin Y; Kuster GM; Benkert P; Jost J; Maceski AM; Rüegg S; Siegemund M; Leppert D; Tschudin-Sutter S; Kuhle J. Annals of Neurology. 2021.Serum neurofilament light chain reflects inflammation-driven neurodegeneration and predicts delayed brain volume loss in early stage of multiple sclerosis.
Srpova B; Uher T; Hrnciarova T; Barro C; Andelova M; Michalak Z; Vaneckova M; Krasensky J; Noskova L; Havrdova EK; Kuhle J; Horakova D. Multiple sclerosis (Houndmills, Basingstoke, England). 2021.Serum neurofilament measurement improves clinical risk scores for outcome prediction after cardiac arrest: results of a prospective study
Hunziker S.; Quinto A.; Ramin-Wright M.; Becker C.; Beck K.; Vincent A.; Tisljar K.; Disanto G.; Benkert P.; Leppert D.; Pargger H.; Marsch S.; RaoulSutter; Peters N.; Kuhle J.. Critical care (London, England). 2021.The cholesterol autoxidation products, 7-ketocholesterol and 7β-hydroxycholesterol are associated with serum neurofilaments in multiple sclerosis.
McComb M; Browne RW; Bhattacharya S; Bodziak ML; Jakimovski D; Weinstock-Guttman B; Kuhle J; Zivadinov R; Ramanathan M. Multiple Sclerosis and Related Disorders. 2021.The Effect of Depression on Health-Related Quality of Life Is Mediated by Fatigue in Persons with Multiple Sclerosis.
Rodgers S; Manjaly ZM; Calabrese P; Steinemann N; Kaufmann M; Salmen A; Chan A; Kesselring J; Kamm CP; Kuhle J; Zecca C; Gobbi C; von Wyl V; Ajdacic-Gross V. Brain sciences. 2021.The Multiple Sclerosis Data Alliance Catalogue Enabling Web-Based Discovery of Metadata from Real-World Multiple Sclerosis Data Sources
Geys L.; Parciak T.; Pirmani A.; McBurney R.; Schmidt H.; Malbasa T.; Ziemssen T.; Bergmann A.; Rojas J.I.; Cristiano E.; Garcia-Merino J.A.; Fernandez O.; Kuhle J.; Gobbi C.; Delmas A.; Simpson-Yap S.; Nag N.; Yamout B.; Steinemann N.; Seeldrayers P.; Dubois B.; van der Mei I.; Stahmann A.; Drulovic J.; Pekmezovic T.; Brola W.; Tintore M.; Kalkers N.; Ivanov R.; Zakaria M.; Naseer M.A.; Hecke W.V.; Grigoriadis N.; Boziki M.; Carra A.; Pawlak M.A.; Dobson R.; Hellwig K.; Gallagher A.; Leocani L.; Costa G.D.; de Carvalho Sousa N.A.; Wijmeersch B.V.; Peeters L.M.. International journal of MS care. 2021.60/30: 60% of the Morbidity-Associated Multiple Sclerosis Disease Burden Comes From the 30% of Persons With Higher Impairments.
Kaufmann M; Puhan MA; Salmen A; Kamm CP; Manjaly ZM; Calabrese P; Schippling S; Müller S; Kuhle J; Pot C; Gobbi C; Steinemann N; von Wyl V; Swiss Multiple Sclerosis Registry (SMSR). Frontiers in Neurology. 2020.A multi-center study of neurofilament assay reliability and inter-laboratory variability.
Gray E; Oeckl P; Amador MDM; Andreasson U; An J; Blennow K; Bowser R; De Schaepdryver M; Heslegrave A; Kuhle J; Maceski A; Koel-Simmelink M; Lamari F; Lombardi V; Malaspina A; Nilsson I; Poesen K; Salachas F; Steinacker P; Teunissen CE; Van Damme P; Zetterberg H; Ludolph A; Jeromin A; Turner MR; Otto M. Amyotrophic lateral sclerosis & frontotemporal degeneration. 2020.A multimodal approach to assess the validity of atrophied T2-lesion volume as an MRI marker of disease progression in multiple sclerosis.
Tavazzi E; Bergsland N; Kuhle J; Jakimovski D; Ramanathan M; Maceski AM; Tomic D; Hagemeier J; Kropshofer H; Leppert D; Dwyer MG; Weinstock-Guttman B; Benedict RHB; Zivadinov R. Journal of Neurology. 2020.Apolipoproteins AI and E are associated with neuroaxonal injury to gray matter in multiple sclerosis.
McComb M; Parambi R; Browne RW; Bodziak ML; Jakimovski D; Bergsland N; Maceski A; Weinstock-Guttman B; Kuhle J; Zivadinov R; Ramanathan M. Multiple Sclerosis and Related Disorders. 2020.Association of neuronal injury blood marker neurofilament light chain with mild-to-moderate COVID-19.
Ameres M; Brandstetter S; Toncheva AA; Kabesch M; Leppert D; Kuhle J; Wellmann S. . 2020.Blood neurofilament light levels segregate treatment effects in multiple sclerosis.
Delcoigne B; Manouchehrinia A; Barro C; Benkert P; Michalak Z; Kappos L; Leppert D; Tsai JA; Plavina T; Kieseier BC; Lycke J; Alfredsson L; Kockum I; Kuhle J; Olsson T; Piehl F. Neurology. 2020.Confounding effect of blood volume and body mass index on blood neurofilament light chain levels.
Manouchehrinia A; Piehl F; Hillert J; Kuhle J; Alfredsson L; Olsson T; Kockum I. Annals of Clinical and Translational Neurology. 2020.Development and validation of the self-reported disability status scale (SRDSS) to estimate EDSS-categories.
Kaufmann M; Salmen A; Barin L; Puhan MA; Calabrese P; Kamm CP; Gobbi C; Kuhle J; Manjaly ZM; Ajdacic-Gross V; Schafroth S; Bottignole B; Ammann S; Zecca C; D'Souza M; von Wyl V; Swiss Multiple Sclerosis Registry (SMSR). Multiple Sclerosis and Related Disorders. 2020.Evaluation of neurofilament light chain in the cerebrospinal fluid and blood as a biomarker for neuronal damage in experimental pneumococcal meningitis.
Le ND; Muri L; Grandgirard D; Kuhle J; Leppert D; Leib SL. Journal of Neuroinflammation. 2020.Evolution of Cortical and White Matter Lesion Load in Early-Stage Multiple Sclerosis: Correlation With Neuroaxonal Damage and Clinical Changes.
Todea RA; Lu PJ; Fartaria MJ; Bonnier G; Du Pasquier R; Krueger G; Bach Cuadra M; Psychogios MN; Kappos L; Kuhle J; Granziera C. Frontiers in Neurology. 2020.Factors influencing patient satisfaction with the first diagnostic consultation in multiple sclerosis: a Swiss Multiple Sclerosis Registry (SMSR) study
Kamm C.P.; Barin L.; Gobbi C.; Pot C.; Calabrese P.; Salmen A.; Achtnichts L.; Kesselring J.; Puhan M.A.; von Wyl V.; Anderseck B.; Calabrese P.; Chan A.; Disanto G.; Engelhardt B.; Gobbi C.; Haussler R.; Kamm C.P.; Kagi S.; Kesselring J.; Kuhle J.; Kurmann R.; Lotter C.; Luyckx K.; Merkler D.; Monin P.; Muller S.; Nedeltchev K.; Pot C.; Puhan M.A.; Rapold I.; Salmen A.; Schippling S.; Vaney C.; von Wyl V.. Journal of Neurology. 2020.Growth differentiation factor 15 is increased in stable MS.
Amstad A; Coray M; Frick C; Barro C; Oechtering J; Amann M; Wischhusen J; Kappos L; Naegelin Y; Kuhle J; Mehling M. Neurology(R) neuroimmunology & neuroinflammation. 2020.Gut microbiota-specific IgA(+) B cells traffic to the CNS in active multiple sclerosis.
Pröbstel AK; Zhou X; Baumann R; Wischnewski S; Kutza M; Rojas OL; Sellrie K; Bischof A; Kim K; Ramesh A; Dandekar R; Greenfield AL; Schubert RD; Bisanz JE; Vistnes S; Khaleghi K; Landefeld J; Kirkish G; Liesche-Starnecker F; Ramaglia V; Singh S; Tran EB; Barba P; Zorn K; Oechtering J; Forsberg K; Shiow LR; Henry RG; Graves J; Cree BAC; Hauser SL; Kuhle J; Gelfand JM; Andersen PM; Schlegel J; Turnbaugh PJ; Seeberger PH; Gommerman JL; Wilson MR; Schirmer L; Baranzini SE. Science Immunology. 2020.Influence of age at disease onset on future relapses and disability progression in patients with multiple sclerosis on immunomodulatory treatment.
von Wyl V; Décard BF; Benkert P; Lorscheider J; Hänni P; Lienert C; Kuhle J; Derfuss T; Kappos L; Yaldizli Ö. European Journal of Neurology. 2020.Kappa free light chains is a valid tool in the diagnostics of MS: A large multicenter study.
Leurs CE; Twaalfhoven H; Lissenberg-Witte BI; van Pesch V; Dujmovic I; Drulovic J; Castellazzi M; Bellini T; Pugliatti M; Kuhle J; Villar LM; Alvarez-Cermeño JC; Alvarez-Lafuente R; Hegen H; Deisenhammer F; Walchhofer LM; Thouvenot E; Comabella M; Montalban X; Vécsei L; Rajda C; Galimberti D; Scarpini E; Altintas A; Rejdak K; Frederiksen JL; Pihl-Jensen G; Jensen P; Khalil M; Voortman MM; Fazekas F; Saiz A; La Puma D; Vercammen M; Vanopdenbosch L; Uitdehaag B; Killestein J; Bridel C; Teunissen C. Multiple sclerosis (Houndmills, Basingstoke, England). 2020.Long-term prognostic value of longitudinal measurements of blood neurofilament levels.
Häring DA; Kropshofer H; Kappos L; Cohen JA; Shah A; Meinert R; Leppert D; Tomic D; Kuhle J. Neurology(R) neuroimmunology & neuroinflammation. 2020.Lymphocyte recovery after fingolimod discontinuation in patients with MS.
Nagy S; Kuhle J; Derfuss T. Neurology(R) neuroimmunology & neuroinflammation. 2020.Monitoring of radiologic disease activity by serum neurofilaments in MS.
Uher T; Schaedelin S; Srpova B; Barro C; Bergsland N; Dwyer M; Tyblova M; Vodehnalova K; Benkert P; Oechtering J; Leppert D; Naegelin Y; Krasensky J; Vaneckova M; Kubala Havrdova E; Kappos L; Zivadinov R; Horakova D; Kuhle J; Kalincik T. Neurology(R) neuroimmunology & neuroinflammation. 2020.Muscle stiffness, gait instability, and liver cirrhosis in Wilson's disease.
Kronlage C; Hardmeier M; Bally S; Scholz MC; Bucher HC; Müller OK; Winterhalder C; Mongiat M; Müller J; Polymeris A; Weber M; Lausberg C; Kassi E; Kuhle J; Kappos L; Hermann W; Bernsmeier C; Yaldizli Ö. The Lancet. 2020.Neurofilament light levels are associated with long-term outcomes in multiple sclerosis.
Kuhle J; Plavina T; Barro C; Disanto G; Sangurdekar D; Singh CM; de Moor C; Engle B; Kieseier BC; Fisher E; Kappos L; Rudick RA; Goyal J. Multiple sclerosis (Houndmills, Basingstoke, England). 2020.Neurofilaments: neurobiological foundations for biomarker applications.
Gafson AR; Barthélemy NR; Bomont P; Carare RO; Durham HD; Julien JP; Kuhle J; Leppert D; Nixon RA; Weller RO; Zetterberg H; Matthews PM. Brain. 2020.Neurofilaments in spinocerebellar ataxia type 3: blood biomarkers at the preataxic and ataxic stage in humans and mice.
Wilke C; Haas E; Reetz K; Faber J; Garcia-Moreno H; Santana MM; van de Warrenburg B; Hengel H; Lima M; Filla A; Durr A; Melegh B; Masciullo M; Infante J; Giunti P; Neumann M; de Vries J; Pereira de Almeida L; Rakowicz M; Jacobi H; Schüle R; Kaeser SA; Kuhle J; Klockgether T; Schöls L; SCA3 neurofilament study group; Barro C; Hübener-Schmid J; Synofzik M. EMBO Molecular Medicine. 2020.Neuroprotective associations of apolipoproteins A-I and A-II with neurofilament levels in early multiple sclerosis.
McComb M; Krikheli M; Uher T; Browne RW; Srpova B; Oechtering J; Maceski AM; Tyblova M; Jakimovski D; Ramasamy DP; Bergsland N; Krasensky J; Noskova L; Fialova L; Weinstock-Guttman B; Havrdova EK; Vaneckova M; Zivadinov R; Horakova D; Kuhle J; Ramanathan M. Journal of Clinical Lipidology. 2020.New and enlarging white matter lesions adjacent to the ventricle system and thalamic atrophy are independently associated with lateral ventricular enlargement in multiple sclerosis.
Sinnecker T; Ruberte E; Schädelin S; Canova V; Amann M; Naegelin Y; Penner IK; Müller J; Kuhle J; Décard B; Derfuss T; Kappos L; Granziera C; Wuerfel J; Magon S; Yaldizli Ö. Journal of Neurology. 2020.NfL and pNfH are increased in Friedreich's ataxia.
Hayer SN; Liepelt I; Barro C; Wilke C; Kuhle J; Martus P; Schöls L; EFACTS study group. Journal of Neurology. 2020.Plasma neurofilament light chain: an early biomarker for hereditary ATTR amyloid polyneuropathy.
Maia LF; Maceski A; Conceição I; Obici L; Magalhães R; Cortese A; Leppert D; Merlini G; Kuhle J; Saraiva MJ. Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis. 2020.Plasma neurofilament light levels are associated with risk of disability in multiple sclerosis.
Manouchehrinia A; Stridh P; Khademi M; Leppert D; Barro C; Michalak Z; Benkert P; Lycke J; Alfredsson L; Kappos L; Piehl F; Olsson T; Kuhle J; Kockum I. Neurology. 2020.Ratio and index of Neurofilament light chain indicate its origin in Guillain-Barré Syndrome.
Körtvelyessy P; Kuhle J; Düzel E; Vielhaber S; Schmidt C; Heinius A; Leypoldt F; Schraven B; Reinhold D; Leppert D; Goihl A. Annals of Clinical and Translational Neurology. 2020.Safety and efficacy of MD1003 (high-dose biotin) in patients with progressive multiple sclerosis (SPI2): a randomised, double-blind, placebo-controlled, phase 3 trial
Cree B.; Cutter G.; Wolinsky J.S.; Freedman M.; Comi G.; Giovannoni G.; Hartung H.-P.; Arnold D.; Kuhle J.; Block V.; Munschauer F.E.; Sedel F.; Lublin F.D.; Reingold S.; Duquette P.; Derfuss T.; Fazekas F.; Sormani M.P.; Lisak R.P.; Graves J.; Krieger S.; Zabad R.K.; Newsome S.; Barton J.; MacDonell R.; Marriott M.; De Klippel N.; Laureys G.; Willekens B.; Devonshire V.; Freedman M.; Girard J.M.; Giacomini P.; McKelvey R.; Selchen D.; Vorobeychik G.; Witkowski L.; Ampapa R.; Preiningerova J.L.; Meluzinova E.; Talab R.; Vachova M.; Aktas O.; Buttmann M.; Birte E.-H.; Kuempfel T.; Friedemann P.; Rau D.; Reifschneider G.; Sokolowski P.; Tumani H.; Satori M.; Pozzilli C.; Klosek A.; Koscielniak J.; Waldemar F.; Zajda M.; Gonzalez R.A.; Ayuso G.I.; Sanchez V.F.; Guevara C.O.; Rodriguez J.E.M.; Montalban X.; Ramio-Torrenta L.; Brundin L.; Lycke J.; Terzi M.; Guadagno J.; Mahad D.; Pace A.; Schmierer K.; Toosy A.; Webb S.; Agius M.; Amezcua L.; Apperson M.; Bagert B.; Bandari D.; Bernitsas E.; Calkwood J.; Carter J.; Cohen B.; Conway D.; Cooper J.; Corboy J.; Coyle P.; Cree B.; Freedman M.; Ford C.; Fox E.; Goldman M.; Greenberg B.; Kita M.; Leist T.; Lynch S.; Miller A.; Moses H.; Naismith R.; Picone M.A.; Perminder B.; Rae-Grant A.; Rammohan K.; Reder A.; Riley C.; Robertson D.; Rowe V.; Saidha S.; Samkoff L.; Severson C.; Smoot K.; Stoll S.; Trudell R.; Weinstock-Guttman B.; Yathiraj S.. The Lancet Neurology. 2020.Serum glial fibrillary acidic protein correlates with multiple sclerosis disease severity.
Högel H; Rissanen E; Barro C; Matilainen M; Nylund M; Kuhle J; Airas L. Multiple sclerosis (Houndmills, Basingstoke, England). 2020.Serum Neurofilament Levels in Children With Febrile Seizures and in Controls.
Evers KS; Hügli M; Fouzas S; Kasser S; Pohl C; Stoecklin B; Bernasconi L; Kuhle J; Wellmann S. Frontiers in neuroscience. 2020.Serum neurofilament light as a biomarker in progressive multiple sclerosis.
Kapoor R; Smith KE; Allegretta M; Arnold DL; Carroll W; Comabella M; Furlan R; Harp C; Kuhle J; Leppert D; Plavina T; Sellebjerg F; Sincock C; Teunissen CE; Topalli I; von Raison F; Walker E; Fox RJ. Neurology. 2020.Serum neurofilament light chain and optical coherence tomography measures in MS: A longitudinal study.
Tavazzi E; Jakimovski D; Kuhle J; Hagemeier J; Ozel O; Ramanathan M; Barro C; Bergsland N; Tomic D; Kropshofer H; Leppert D; Michalak Z; Lincoff N; Dwyer MG; Benedict RHB; Weinstock-Guttman B; Zivadinov R. Neurology(R) neuroimmunology & neuroinflammation. 2020.Serum Neurofilament Light Chain Is Associated with Incident Lacunes in Progressive Cerebral Small Vessel Disease.
Peters N; van Leijsen E; Tuladhar AM; Barro C; Konieczny MJ; Ewers M; Lyrer P; Engelter ST; Kuhle J; Duering M; de Leeuw FE. Journal of stroke. 2020.Serum neurofilament light chain is a useful biomarker in pediatric multiple sclerosis.
Reinert MC; Benkert P; Wuerfel J; Michalak Z; Ruberte E; Barro C; Huppke P; Stark W; Kropshofer H; Tomic D; Leppert D; Kuhle J; Brück W; Gärtner J. Neurology(R) neuroimmunology & neuroinflammation. 2020.Serum neurofilament light chain level associations with clinical and cognitive performance in multiple sclerosis: A longitudinal retrospective 5-year study.
Jakimovski D; Zivadinov R; Ramanthan M; Hagemeier J; Weinstock-Guttman B; Tomic D; Kropshofer H; Fuchs TA; Barro C; Leppert D; Yaldizli Ö; Kuhle J; Benedict RH. Multiple sclerosis (Houndmills, Basingstoke, England). 2020.Serum neurofilament light chain levels are associated with white matter integrity in autosomal dominant Alzheimer's disease.
Schultz SA; Strain JF; Adedokun A; Wang Q; Preische O; Kuhle J; Flores S; Keefe S; Dincer A; Ances BM; Berman SB; Brickman AM; Cash DM; Chhatwal J; Cruchaga C; Ewers M; Fox NN; Ghetti B; Goate A; Graff-Radford NR; Hassenstab JJ; Hornbeck R; Jack C Jr; Johnson K; Joseph-Mathurin N; Karch CM; Koeppe RA; Lee AKW; Levin J; Masters C; McDade E; Perrin RJ; Rowe CC; Salloway S; Saykin AJ; Sperling R; Su Y; Villemagne VL; Vöglein J; Weiner M; Xiong C; Fagan AM; Morris JC; Bateman RJ; Benzinger TLS; Jucker M; Gordon BA; Dominantly Inherited Alzheimer Network. Neurobiology of disease. 2020.Serum Neurofilament Light Chain Levels in Patients With Presymptomatic Multiple Sclerosis.
Bjornevik K; Munger KL; Cortese M; Barro C; Healy BC; Niebuhr DW; Scher AI; Kuhle J; Ascherio A. JAMA neurology. 2020.Serum neurofilament light chains in MS: Association with the Timed Up and Go.
Allali G; Kuhle J; Breville G; Leppert D; Armand S; Lalive PH. Neurology(R) neuroimmunology & neuroinflammation. 2020.Serum neurofilament light in atrial fibrillation: clinical, neuroimaging and cognitive correlates.
Polymeris AA; Coslovksy M; Aeschbacher S; Sinnecker T; Benkert P; Kobza R; Beer J; Rodondi N; Fischer U; Moschovitis G; Monsch AU; Springer A; Schwenkglenks M; Wuerfel J; De Marchis GM; Lyrer PA; Kühne M; Osswald S; Conen D; Kuhle J; Bonati LH; and for the Swiss-AF Investigators. Brain communications. 2020.Serum neurofilament light levels in normal aging and their association with morphologic brain changes.
Khalil M; Pirpamer L; Hofer E; Voortman MM; Barro C; Leppert D; Benkert P; Ropele S; Enzinger C; Fazekas F; Schmidt R; Kuhle J. Nature Communications. 2020.Serum NfL levels should be used to monitor multiple sclerosis evolution - Yes.
Leppert D; Kuhle J. Multiple sclerosis (Houndmills, Basingstoke, England). 2020.Temporal association of sNfL and gad-enhancing lesions in multiple sclerosis.
Rosso M; Gonzalez CT; Healy BC; Saxena S; Paul A; Bjornevik K; Kuhle J; Benkert P; Leppert D; Guttmann C; Bakshi R; Weiner HL; Chitnis T. Annals of Clinical and Translational Neurology. 2020.The weak association between neurofilament levels at multiple sclerosis onset and cognitive performance after 9 years.
Friedova L; Motyl J; Srpova B; Oechtering J; Barro C; Vodehnalova K; Andelova M; Noskova L; Fialová L; Havrdova EK; Horakova D; Benedict RH; Kuhle J; Uher T. Multiple Sclerosis and Related Disorders. 2020.Validation of Quantitative Scores Derived From Motor Evoked Potentials in the Assessment of Primary Progressive Multiple Sclerosis: A Longitudinal Study.
Hardmeier M; Schindler C; Kuhle J; Fuhr P. Frontiers in Neurology. 2020.Vitamin D, smoking, EBV, and long-term cognitive performance in MS: 11-year follow-up of BENEFIT.
Cortese M; Munger KL; Martínez-Lapiscina EH; Barro C; Edan G; Freedman MS; Hartung HP; Montalbán X; Foley FW; Penner IK; Hemmer B; Fox EJ; Schippling S; Wicklein EM; Kappos L; Kuhle J; Ascherio A; BENEFIT Study Group. Neurology. 2020.Vitamin D(3) supplementation and neurofilament light chain in multiple sclerosis.
Smolders J; Mimpen M; Oechtering J; Damoiseaux J; van den Ouweland J; Hupperts R; Kuhle J. Acta neurologica Scandinavica. 2020.Xenogeneic Neu5Gc and self-glycan Neu5Ac epitopes are potential immune targets in MS.
Boligan KF; Oechtering J; Keller CW; Peschke B; Rieben R; Bovin N; Kappos L; Cummings RD; Kuhle J; von Gunten S; Lünemann JD. Neurology(R) neuroimmunology & neuroinflammation. 2020.A case series on the value of tau and neurofilament protein levels to predict and detect delirium in cardiac surgery patients.
Saller T; Petzold A; Zetterberg H; Kuhle J; Chappell D; von Dossow V; Klawitter F; Schurholz T; Hagl C; Reuter DA; Zwissler B; Ehler J. Biomedical Papers. 2019.A Framework for Estimating the Burden of Chronic Diseases: Design and Application in the Context of Multiple Sclerosis.
Kaufmann M; Puhan MA; Kuhle J; Yaldizli Ö; Magnusson T; Kamm CP; Calabrese P; von Wyl V. Frontiers in Neurology. 2019.Age at disease onset and clinical outcomes in patients with multiple sclerosis on immunomodulatory treatment
von Wyl, V.; Decard, B.; Benkert, P.; Lorscheider, J.; Hanni, P.; Lienert, C.; Kuhle, J.; Derfuss, T.; Kappos, L.; Yaldizli, O.. Multiple sclerosis (Houndmills, Basingstoke, England). 2019.Ageing with multiple sclerosis: the role of calendar age and disease duration for disease outcomes and co-morbidity occurrence in the swiss multiple sclerosis registry
Salmen, A.; Chan, A.; Calabrese, P.; Kamm, C. P.; Kuhle, J.; Schippling, S.; von Wyl, V.. Multiple sclerosis (Houndmills, Basingstoke, England). 2019.Alemtuzumab Reduces Serum Neurofilament Light Chain Levels in Relapsing-Remitting Multiple Sclerosis Patients with Highly Active Disease: CARE-MS I
Kuhle, Jens; Daizadeh, Nadia; Barro, Christian; Michalak, Zuzanna; Leppert, David; Godin, Jean; Shankara, Srinivas; Samad, Tarek; Jacobs, Alan; Chung, Luke; Roesch, Nora; Kaiser, Carina; Havari, Evis; Kappos, Ludwig. Multiple sclerosis (Houndmills, Basingstoke, England). 2019.Analysis of GFAP and NfL as serum biomarkers in a prospective cohort of patients with NMOSD
Schindler, P.; Grittner, U.; Oechtering, J.; Leppert, D.; Siebert, N.; Oertel, F. C.; Zimmermann, H.; Brandt, A. U.; Bellmann-Strobl, J.; Jarius, S.; Paul, F.; Kuhle, J.; Ruprecht, K.. Multiple sclerosis (Houndmills, Basingstoke, England). 2019.An evaluation of axonal and myelin damage in multiple sclerosis lesions in living patients using myelin water and multi-shell diffusion MRI
Rahmanzadeh, R.; Lu, P. -J.; Weigel, M.; Nguyen, T. D.; Schiavi, S.; Wang, Y.; Radue, E. -W.; Kuhle, J.; Kappos, L.; Granziera, C.. European Journal of Neurology . 2019.Anti-inflammatory disease-modifying treatment and disability progression in primary progressive multiple sclerosis: a cohort study.
Lorscheider J; Kuhle J; Izquierdo G; Lugaresi A; Havrdova E; Horakova D; Hupperts R; Duquette P; Girard M; Prat A; Grand'Maison F; Grammond P; Sola P; Ferraro D; Trojano M; Ramo-Tello C; Lechner-Scott J; Pucci E; Solaro C; Slee M; Van Pesch V; Sanchez Menoyo JL; van der Walt A; Butzkueven H; Kappos L; Kalincik T; MSBase Study Group. European Journal of Neurology. 2019.Association between Serum Neurofilament Light and Established White Matter Neuroimaging Markers in Autosomal Dominant Alzheimer Disease
Schultz, Stephanie; Adedokun, Adedamola; Strain, Jeremy; Wang, Qing; Preische, Oliver; Kuhle, Jens; Morris, John; Bateman, Randall; Jucker, Mathias; Benzinger, Tammie; Gordon, Brian. Annals of Neurology. 2019.Association Between Serum Neurofilament Light Chain Levels and Long-term Disease Course Among Patients With Multiple Sclerosis Followed up for 12 Years.
Cantó E; Barro C; Zhao C; Caillier SJ; Michalak Z; Bove R; Tomic D; Santaniello A; Häring DA; Hollenbach J; Henry RG; Cree BAC; Kappos L; Leppert D; Hauser SL; Benkert P; Oksenberg JR; Kuhle J. JAMA neurology. 2019.Association of clinical frontal release signs and cognitive impairment - a prospective study with 119 multiple sclerosis patients
Fuertes, N. Cerda; Schaedelin, S.; Derfuss, T.; Kappos, L.; Kuhle, J.; Mitrovic, T.; Calabrese, P.; Decard, B. F.. Multiple sclerosis (Houndmills, Basingstoke, England). 2019.Axonal and myelin injury in white matter and cortex of relapsing-remitting and progressive multiple sclerosis patients: a combined myelin water and multi-shell diffusion MRI study
Rahmanzadeh, R.; Lu, P. -J.; Weigel, M.; Galbusera, R.; Nguyen, T. D.; Schiavi, S.; Wang, Y.; La Rosa, F.; Cuadra, M. Bach; Radue, E. -W.; Kuhle, J.; Kappos, L.; Granziera, C.. Multiple sclerosis (Houndmills, Basingstoke, England). 2019.Axonal damage explains part of and extends beyond the diffuse pathology evidenced by T1 mapping in normal-appearing white matter of multiple sclerosis patients
Rahmanzadeh, R.; Lu, P. -J.; Weigel, M.; Galbusera, R.; La Rosa, F.; Cuadra, M. Bach; Schiavi, S.; Radue, E. -W.; Kuhle, J.; Kappos, L.; Granziera, C.. Multiple sclerosis (Houndmills, Basingstoke, England). 2019.Blood neurofilament light as a potential endpoint in Phase 2 studies in MS.
Sormani MP; Haering DA; Kropshofer H; Leppert D; Kundu U; Barro C; Kappos L; Tomic D; Kuhle J. Annals of Clinical and Translational Neurology. 2019.Blood neurofilament light chain: ready for the clinic?
Kuhle, J.; Piehl, F.; Willemse, E.. Multiple sclerosis (Houndmills, Basingstoke, England). 2019.Blood neurofilament light chain as a biomarker of MS disease activity and treatment response.
Kuhle J; Kropshofer H; Haering DA; Kundu U; Meinert R; Barro C; Dahlke F; Tomic D; Leppert D; Kappos L. Neurology. 2019.Blood neurofilament light chain at the doorstep of clinical application.
Leppert D; Kuhle J. Neurology(R) neuroimmunology & neuroinflammation. 2019.Blood neurofilament light levels are lowered to a healthy donor range in patients with RMS and PPMS following ocrelizumab treatment
Bar-Or, A.; Thanei, G-A.; Harp, C. T.; Cross, A. H.; Hauser, S. L.; Kuhle, J.; Leppert, D.; Oksenberg, J.; Model, F.; Fiore, D.; Koendgen, H.; Mehta, L.; Hendricks, R.; Fischer, S.; Manfrini, M.; Herman, A. E.. Multiple sclerosis (Houndmills, Basingstoke, England). 2019.Classification of multiple sclerosis patients based on patterns of volume loss in the CNS
Tsagkas, C.; Parmar, K.; Pezold, S.; Barro, C.; Chakravarty, M. M.; Gaetano, L.; Naegelin, Y.; Amann, M.; Papadopoulou, A.; Wuerfel, J.; Kappos, L.; Kuhle, J.; Sprenger, T.; Granziera, C.; Magon, S.. Multiple sclerosis (Houndmills, Basingstoke, England). 2019.Combined omics analysis of cerebrospinal fluid is able to predict conversion from clinically isolated syndrome to clinically definite MS within 4 years
Probert, F.; Yeo, T.; Sealey, M.; Palace, J.; Leppert, D.; Kuhle, J.; Anthony, D. C.. Multiple sclerosis (Houndmills, Basingstoke, England). 2019.Comparison of fingolimod, dimethyl fumarate and teriflunomide for multiple sclerosis.
Kalincik T; Kubala Havrdova E; Horakova D; Izquierdo G; Prat A; Girard M; Duquette P; Grammond P; Onofrj M; Lugaresi A; Ozakbas S; Kappos L; Kuhle J; Terzi M; Lechner-Scott J; Boz C; Grand'Maison F; Prevost J; Sola P; Ferraro D; Granella F; Trojano M; Bergamaschi R; Pucci E; Turkoglu R; McCombe PA; Pesch VV; Van Wijmeersch B; Solaro C; Ramo-Tello C; Slee M; Alroughani R; Yamout B; Shaygannejad V; Spitaleri D; Sánchez-Menoyo JL; Ampapa R; Hodgkinson S; Karabudak R; Butler E; Vucic S; Jokubaitis V; Spelman T; Butzkueven H. Journal of Neurology, Neurosurgery and Psychiatry. 2019.Correlations between serum and CSF pNfH levels in ALS, FTD and controls: a comparison of three analytical approaches.
Wilke C; Pujol-Calderón F; Barro C; Stransky E; Blennow K; Michalak Z; Deuschle C; Jeromin A; Zetterberg H; Schüle R; Höglund K; Kuhle J; Synofzik M. Clinical chemistry and laboratory medicine. 2019.Deep learning analysis applied to multi-parametric advanced MRI shows higher myelin content and neurite density in juxtacortical lesions compared to periventricular lesions
Lu, P. -J.; Rahmanzadeh, R.; Galbusera, R.; Odry, B.; Weigel, M.; La Rosa, F.; Cuadra, M. Bach; Nguyen, T.; Wang, Y.; Daducci, A.; Kuhle, J.; Cattin, P.; Kappos, L.; Granziera, C.. Multiple sclerosis (Houndmills, Basingstoke, England). 2019.Diagnostic Value of Cerebrospinal Fluid Neurofilament Light Protein in Neurology: A Systematic Review and Meta-analysis.
Bridel C; van Wieringen WN; Zetterberg H; Tijms BM; Teunissen CE; and the NFL Group; Alvarez-Cermeño JC; Andreasson U; Axelsson M; Bäckström DC; Bartos A; Bjerke M; Blennow K; Boxer A; Brundin L; Burman J; Christensen T; Fialová L; Forsgren L; Frederiksen JL; Gisslén M; Gray E; Gunnarsson M; Hall S; Hansson O; Herbert MK; Jakobsson J; Jessen-Krut J; Janelidze S; Johannsson G; Jonsson M; Kappos L; Khademi M; Khalil M; Kuhle J; Landén M; Leinonen V; Logroscino G; Lu CH; Lycke J; Magdalinou NK; Malaspina A; Mattsson N; Meeter LH; Mehta SR; Modvig S; Olsson T; Paterson RW; Pérez-Santiago J; Piehl F; Pijnenburg YAL; Pyykkö OT; Ragnarsson O; Rojas JC; Romme Christensen J; Sandberg L; Scherling CS; Schott JM; Sellebjerg FT; Simone IL; Skillbäck T; Stilund M; Sundström P; Svenningsson A; Tortelli R; Tortorella C; Trentini A; Troiano M; Turner MR; van Swieten JC; Vågberg M; Verbeek MM; Villar LM; Visser PJ; Wallin A; Weiss A; Wikkelsø C; Wild EJ. JAMA neurology. 2019.Disability progression unrelated to relapses in relapsing-remitting multiple sclerosis: insights from the Swiss multiple sclerosis cohort study
Lorscheider, J.; Benkert, P.; Schadelin, S.; Yaldizli, O.; Derfuss, T.; Lalive, P.; Pot, C.; Mueller, S.; Vehoff, J.; Sinnecker, T.; Wurfel, J.; Achtnichts, L.; Findling, O.; Nedeltchev, K.; Du Pasquier, R.; Disanto, G.; Zecca, C.; Kamm, C.; Salmen, A.; Chan, A.; Granziera, C.; Gobbi, C.; Kappos, L.; Kuhle, J.. Multiple sclerosis (Houndmills, Basingstoke, England). 2019.Disease course in primary progressive multiple sclerosis: validation of a prediction model using multimodal evoked potentials
Hardmeier, M.; Schlaeger, R.; Lascano, A. M.; Toffolet, L.; Schindler, C.; Gobbi, C.; Lalive, P.; Kuhle, J.; Kappos, L.; Fuhr, P.. Multiple sclerosis (Houndmills, Basingstoke, England). 2019.Early differentiating characteristics of clinically stable patients on low efficacy immunomodulatory treatment over long-term follow-up
Hrnciarova, T.; Uher, T.; Krasensky, J.; Andelova, M.; Vodehnalova, K.; Tyblova, M.; Srpova, B.; Barro, C.; Oechtering, J.; Havrdova, E. Kubala; Kuhle, J.; Vaneckova, M.; Horakova, D.. Multiple sclerosis (Houndmills, Basingstoke, England). 2019.Effect of Alemtuzumab on Serum Neurofilament Light Chain Levels: Comparison to SC IFNB-1a and Assessment Over 7 Years (CARE-MS I)
Kuhle, Jens; Daizadeh, Nadia; Barro, Christian; Michalak, Zuzanna; Leppert, David; Godin, Jean; Shankara, Srinivas; Samad, Tarek A.; Jacobs, Alan; Chung, Luke; Roesch, Nora; Kaiser, Carina; Kappos, Ludwig; Havari, Evis. Neurology. 2019.Effect of Alemtuzumab on serum neurofilament light chain levels in RRMS patients with or without highly active disease: comparison with SC IFNB-1a and 7-year assessment (CARE-MS I)
Kuhle, J.; Daizadeh, N.; Barro, C.; Michalak, Z.; Leppert, D.; Godin, J.; Shankara, S.; Samad, T. A.; Jacobs, A.; Chung, L.; Roesch, N.; Kaiser, C.; Mitchell, C.; Kappos, L.; Havari, E.. Multiple sclerosis (Houndmills, Basingstoke, England). 2019.Effect of Ibudilast on Neurofilament-light Chain in Progressive MS: Analysis from a Phase II Trial
Fox, Robert; Karafa, Matthew; Konig, Victoria; Natarajan, Natarajan; Barro, Christian; Bermel, Robert; Coffey, Christopher; Goodman, Andrew; Klawiter, Eric; Matsuda, Kazuko; Naismith, Robert; Kuhle, Jens. Neurology. 2019.Effect of interferon beta-1a treatment on serum neurofilament light chain levels in patients with a first clinical demyelinating event in the REFLEX trial
Kuhle, J.; Leppert, D.; Comi, G.; De Stefano, N.; Kappos, L.; Freedman, M. S.; Roy, S.; Issard, D.. Multiple sclerosis (Houndmills, Basingstoke, England). 2019.Elevated levels of plasma neurofilament light at months 6 and 12 after fingolimod treatment initiation predict disability worsening in patients with relapsing-remitting multiple sclerosis
Kuhle, J.; Danner, S.; Meinert, R.; Leppert, D.; Kappos, L.; Tomic, D.; Kropshofer, H.. Multiple sclerosis (Houndmills, Basingstoke, England). 2019.Estimating and accounting for the effect of MRI scanner changes on longitudinal whole-brain volume change measurements
Sinnecker, T.; Schadelin, S.; Ruberte, E.; Canova, V.; Amann, M.; Magon, S.; Lieb, J. M.; Naegelin, Y.; Kuhle, J.; Derfuss, T.; Kappos, L.; Wuerfel, J.; Granziera, C.; Yaldizli, O.. Multiple sclerosis (Houndmills, Basingstoke, England). 2019.Hepatitis E virus infections in patients with MS on oral disease-modifying treatment.
Diebold M; Fischer-Barnicol B; Tsagkas C; Kuhle J; Kappos L; Derfuss T; Décard BF. Neurology(R) neuroimmunology & neuroinflammation. 2019.High-density lipoprotein cholesterol is associated with multiple sclerosis fatigue: A fatigue-metabolism nexus?
Browne RW; Jakimovski D; Ziliotto N; Kuhle J; Bernardi F; Weinstock-Guttman B; Zivadinov R; Ramanathan M. Journal of Clinical Lipidology. 2019.High-dose vitamin D-3 supplementation in multiple sclerosis is not associated with lower circulating neurofilament light chain levels
Smolders, J.; Oechtering, J.; Damoiseaux, J.; Van den Ouweland, J.; Hupperts, R.; Kuhle, J.. Multiple sclerosis (Houndmills, Basingstoke, England). 2019.Higher serum neurofilament light chain levels are associated with lower self-reported quality of life in the Swiss MS registry and the Swiss MS cohort-study
Kaufmann, M.; Salmen, A.; Kamm, C. P.; Chan, A.; Schippling, S.; Calabrese, P.; Leppert, D.; Gobbi, C.; Kuhle, J.; von Wyl, V.. Multiple sclerosis (Houndmills, Basingstoke, England). 2019.Impact of parturition on maternal cardiovascular and neuronal integrity in a high risk cohort - a prospective cohort study.
Evers KS; Huhn EA; Fouzas S; Barro C; Kuhle J; Fisch U; Bernasconi L; Lapaire O; Wellmann S. BMC Pregnancy and Childbirth. 2019.Improvements in balance control for multiple sclerosis patients with vibro-tactile biofeedback of trunk sway
Allum, J.; Schouenborg, C.; Lutz, N.; Rust, H.; Fischer-Barnicol, B.; Haller, V.; Kuhle, J.; Derfuss, T.; Kappos, L.; Yaldizli, O.. Multiple sclerosis (Houndmills, Basingstoke, England). 2019.Increased serum neurofilament light chain levels are associated with relapse, MRI disease activity, and need for additional alemtuzumab courses in patients from CARE-MS I
Kuhle, J.; Daizadeh, N.; Barro, C.; Michalak, Z.; Leppert, D.; Godin, J.; Shankara, S.; Chung, L.; Roesch, N.; Kaiser, C.; Samad, T. A.; Jacobs, A.; Havari, E.; Kappos, L.. European Journal of Neurology . 2019.Intrathecal IgG and IgM synthesis are strongly associated with the use of highly effective therapies in relapsing MS in the Swiss MS Cohort Study
Oechtering, J.; Schadelin, S.; Benkert, P.; Disanto, G.; Orleth, A.; Achtnichts, L.; Chan, A.; Derfuss, T.; Du Pasquier, R.; Findling, O.; Granziera, C.; Heijnen, I.; Kamm, C.; Lalive, P.; Leppert, D.; Mueller, S.; Nedeltchev, K.; Pot, C.; Regeniter, A.; Salmen, A.; Sinnecker, T.; Vehoff, J.; Wurfel, J.; Yaldizli, O.; Zecca, C.; Gobbi, C.; Kappos, L.; Kuhle, J.. Multiple sclerosis (Houndmills, Basingstoke, England). 2019.Introducing Machine Learning for full MS patient trajectories improves predictions for disability score progression
De Brouwer, E.; Peeters, L.; Becker, T.; Altintas, A.; Soysal, A.; Van Wijmeersch, B.; Boz, C.; Oreja-Guevara, C.; Gobbi, C.; Solaro, C.; Ramo, C.; Spitaleri, D. L.; Maimone, D.; Aguera-Morales, E.; Cartechini, E.; Butler, E.; Havrdova, E.; Patti, F.; Granella, F.; Grand'Maison, F.; Moore, F.; Verheul, F.; Iuliano, G.; Butzkueven, H.; Lechner-Scott, J.; Kuhle, J.; Sanchez Menoyo, J. L.; Rojas, J. I.; Prevost, J.; Onofrj, M.; Rio, M. E.; Sa, M. J.; Saladino, M. L.; Slee, M.; Barnett, M.; Terzi, M.; Deri, N.; McCombe, P.; Sola, P.; Duquette, P.; Grammond, P.; Ampapa, R.; Alroughani, R.; Hupperts, R.; Turkoglu, R.; Gouider, R.; Fernandez Bolanos, R.; Bergamaschi, R.; Kalincik, T.; Moreau, Y.. Multiple sclerosis (Houndmills, Basingstoke, England). 2019.Longitudinal MRI dynamics of recent small subcortical infarcts and possible predictors.
Pinter D; Gattringer T; Enzinger C; Seifert-Held T; Kneihsl M; Fandler S; Pichler A; Barro C; Eppinger S; Pirpamer L; Bachmaier G; Ropele S; Wardlaw JM; Kuhle J; Khalil M; Fazekas F. Journal of Cerebral Blood Flow and Metabolism. 2019.Long-term Effect of Fingolimod in Reducing Blood Neurofilament Light Levels in Patients with Relapsing-remitting Multiple Sclerosis
Cohen, Jeffrey; Kappos, Ludwig; Tenenbaum, Nadia; Han, Jackie; Kropshofer, Harald; Tomic, Davorka; Kuhle, Jens. Neurology. 2019.Microstructural white matter tract damage measured using DTI-MRI associates with increased serum NFL levels
Saraste, M.; Bezukladova, S.; Matilainen, M.; Tuisku, J.; Rissanen, E.; Sucksdorff, M.; Vuorimaa, A.; Kuhle, J.; Leppert, D.; Airas, L.. Multiple sclerosis (Houndmills, Basingstoke, England). 2019.Monitoring of Subclinical Disease Activity by Serum Neurofilament Light Chain Levels in Multiple Sclerosis
Uher, Tomas; Schaedelin, Sabine; Benova, Barbora; Barro, Christian; Bergsland, Niels; Dwyer, Michael; Tyblova, Michaela; Kucerova, Karolina; Benkert, Pascal; Michalak, Zuzanna; Leppert, David; Naegelin, Yvonne; Krasensky, Jan; Seidl, Zdenek; Vaneckova, Manuela; Havrdova, Eva Kubala; Kappos, Ludwig; Zivadinov, Robert; Horakova, Dana; Kuhle, Jens; Kalincik, Tomas. Neurology. 2019.Multiple sclerosis registries in Europe - An updated mapping survey.
Glaser A; Stahmann A; Meissner T; Flachenecker P; Horáková D; Zaratin P; Brichetto G; Pugliatti M; Rienhoff O; Vukusic S; de Giacomoni AC; Battaglia MA; Brola W; Butzkueven H; Casey R; Drulovic J; Eichstädt K; Hellwig K; Iaffaldano P; Ioannidou E; Kuhle J; Lycke K; Magyari M; Malbaša T; Middleton R; Myhr KM; Notas K; Orologas A; Otero-Romero S; Pekmezovic T; Sastre-Garriga J; Seeldrayers P; Soilu-Hänninen M; Stawiarz L; Trojano M; Ziemssen T; Hillert J; Thalheim C. Multiple Sclerosis and Related Disorders. 2019.Neurofilament light chain levels in blood are predictive of cognitive impairment in patients with secondary progressive multiple sclerosis
Kuhle, J.; Kropshofer, H.; Barro, C.; Meinert, R.; Haring, D.; Leppert, D.; Dahlke, F.; Tomic, D.; Kappos, L.. European Journal of Neurology . 2019.Neurofilament Light Chain Levels In Pregnant Multiple Sclerosis Patients
Pablo Cuello, Juan; Martinez Gines, Maria Luisa; Kuhle, Jens; Garcia Dominguez, Jose Manuel; Lozano Ros, Alberto; Romero Delgado, Fernando; Higueras, Yolanda; Meldana Rivera, Ariana; Goicochea Briceno, Haydee; Garcia Tizon, Santiago; de-Leon Ruiz, Juan; Alvarez Lafuente, Roberto; Inmaculada Dominguez-Mozo, Maria; Perez-Perez, Silvia; Heras, Silvia Medina; Velasco, Jose Ignacio Fernandez; Tejeda-Velarde, Amalia; De Andres, Clara; Villar, Luisa Maria. Neurology. 2019.Neurofilament light chain levels in pregnant multiple sclerosis patients: a prospective cohort study.
Cuello JP; Martínez Ginés ML; Kuhle J; García Domínguez JM; Lozano Ros A; Romero Delgado F; Higueras Y; Meldaña Rivera A; Goicochea Briceño H; García-Tizon Larroca S; De León-Luis J; Michalak Z; Barro C; Álvarez Lafuente R; Medina Heras S; Fernández Velasco JI; Tejeda-Velarde A; Domínguez-Mozo MI; Muriel A; de Andrés C; Villar LM. European Journal of Neurology. 2019.Neurofilament Light Chain Serum Levels Correlate with 10-Year MRI Outcomes in Multiple Sclerosis
Chitnis, Tanuja; Gonzalez, Cindy T.; Healy, Brian C.; Saxena, Shrishti; Rosso, Mattia; Barro, Christian; Michalak, Zuzanna; Paul, Anu; Kivisakk, Pia; Diaz-Cruz, Camilo; Sattarnezhad, Neda; Pierre, Isabelle; Glanz, Bonnie I.; Tomic, Davorka; Kropshofer, Harald; Haring, Dieter A.; Leppert, David; Kappos, Ludwig; Bakshi, Rohit; Weiner, Howard L.; Kuhle, Jens. Multiple sclerosis (Houndmills, Basingstoke, England). 2019.Neurofilament light chains for outcome prediction in ischemic stroke
Uphaus, T.; Groeschel, S.; Kuhle, J.; Weber-Krueger, M.; Wachter, R.; Groeschel, K.. European Journal of Neurology . 2019.Neurofilament Light Chains Predict Outcome After Ischemic Stroke
Uphaus, Timo; Groschel, Sonja; Kuhle, Jens; Weber-Kruger, Mark; Wachter, Rolf; Groschel, Klaus. Stroke. 2019.Neurofilament Light Levels in the Blood of Patients with Secondary Progressive MS are Higher Than in Primary Progressive MS and may Predict Brain Atrophy in Both MS Subtypes
Leppert, D.; Kuhle, J.; Kropshofer, H.; Haring, D. A.; Barro, C.; Dahlke, F.; Tomic, D.; Kappos, L.. Multiple sclerosis (Houndmills, Basingstoke, England). 2019.Neurofilament light test results vary substantially across different assay platforms and assay reagents
Deisenhammer, Florian; Podlesnic, Martina; Kuhle, Jens; Leppert, David; Michalak, Zuzanna; Deisenhammer, Julian; Schanda, Kathrin; Ehling, Rainer; Reindl, Markus. Neurology. 2019.New or enlarging T2 weighted lesions in the white matter near to the ventricle wall and thalamic atrophy are independently associated with lateral ventricular enlargement in multiple sclerosis
Sinnecker, T.; Ruberte, E.; Schadelin, S.; Canova, V.; Amann, M.; Naegelin, Y.; Penner, I. -K.; Kuhle, J.; Decard, B.; Derfuss, T.; Andermatt, S.; Cattin, P.; Kappos, L.; Granziera, C.; Wuerfel, J.; Magon, S.; Yaldizli, O.. Multiple sclerosis (Houndmills, Basingstoke, England). 2019.Ocrelizumab Treatment Effect on Upper Limb Function in PPMS Patients with Disability: Subgroup Results of the ORATORIO Study to Inform the ORATORIO-HAND Study Design
Giovannoni, Gavin; Airas, Laura; Bove, Riley; Boyko, Alexey; Cutter, Gary; Hobart, Jeremy; Kuhle, Jens; Oh, Jiwon; Tur, Carmen; Garas, Monika; Model, Fabian; Manfrini, Marianna; Wolinsky, Jerry S.. Neurology. 2019.Paramagnetic phase rims and serum neurofilaments in relapsing-remitting and progressive multiple sclerosis patients: a combined laboratory-imaging marker of chronic inflammation
Maggi, P.; Kuhle, J.; Weigel, M.; Mathias, A.; Sati, P.; Theaudin, M.; Pot, C.; Van Pesch, V.; Meuli, R.; Kappos, L.; Du Pasquier, R.; Reich, D. S.; Absinta, M.; Granziera, C.. Multiple sclerosis (Houndmills, Basingstoke, England). 2019.PARP-1 deregulation in multiple sclerosis.
Meira M; Sievers C; Hoffmann F; Bodmer H; Derfuss T; Kuhle J; Haghikia A; Kappos L; Lindberg RL. Multiple sclerosis journal - experimental, translational and clinical. 2019.Patterns of care for Multiple Sclerosis in a setting of universal care access: A cross-sectional study.
Barin L; Kaufmann M; Salmen A; Kamm CP; Gobbi C; Kuhle J; Pot C; Chan A; Czaplinski A; Ajdacic-Gross V; Rodgers S; Kesselring J; Puhan MA; von Wyl V; Swiss Multiple Sclerosis Registry. Multiple Sclerosis and Related Disorders. 2019.Plasma glial fibrillary acidic protein correlates with characteristics of advanced disease and treatment response in secondary progressive multiple sclerosis
Kuhle, J.; Kropshofer, H.; Meinert, R.; Maceski, A. M.; Dahlke, F.; Hach, T.; Tomic, D.; Kappos, L.; Leppert, D.. Multiple sclerosis (Houndmills, Basingstoke, England). 2019.Plasma neurofilament light levels are associated with impairments to information processing efficiency in multiple sclerosis
Manouchehrinia, A.; McKay, K. A.; Alfredsson, L.; Peihl, F.; Olsson, T.; Kuhle, J.; Kockum, I.. Multiple sclerosis (Houndmills, Basingstoke, England). 2019.Plasma proteome in multiple sclerosis disease progression.
Malekzadeh A; Leurs C; van Wieringen W; Steenwijk MD; Schoonheim MM; Amann M; Naegelin Y; Kuhle J; Killestein J; Teunissen CE. Annals of Clinical and Translational Neurology. 2019.Potential translation of neurofilament light chain (NfL) as a safety biomarker for neurotoxicity in spinal muscular atrophy
Theil, D.; de Pommerol, H. Jullien; Kuhle, J.; Brees, D.; Tritto, E.; Valentin, M.; Hartmann, A.. Neuromuscular Disorders. 2019.Progression independent of relapse activity (PIRA) in relapsing-remitting multiple sclerosis patients on first-line immunomodulatory treatment with fingolimod vs. platform injectables
von Wyl, V.; Benkert, P.; Lorscheider, J.; Hanni, P.; Lienert, C.; Decard, B.; Kuhle, J.; Derfuss, T.; Kappos, L.; Yaldizli, O.. Multiple sclerosis (Houndmills, Basingstoke, England). 2019.Real-world experience with Ocrelizumab in the MSBase Registry
Butzkueven, H.; Spelman, T.; Patti, F.; Ozakbas, S.; Eichau, S.; Alroughani, R.; Terzi, M.; Boz, C.; Grand'Maison, F.; Grammond, P.; Kalincik, T.; Van Pesch, V.; Lechner-Scott, J.; Barnett, M.; Kuhle, J.; Hodgkinson, S.; Skibina, O.; Soysal, A.; Butler, E.; Slee, M.; Prevost, J.; Laureys, G.; Macdonell, R.; van Beek, J.; Craveiro, L.; Wormser, D.; Muros-Le Rouzic, E.. Multiple sclerosis (Houndmills, Basingstoke, England). 2019.Serum Biomarkers for MS Related to Inflammatory and Degenerating Processes
Leppert, David; Kuhle, Jens. Multiple sclerosis (Houndmills, Basingstoke, England). 2019.Serum GFAP and neurofilament light as biomarkers of disease activity and disability in NMOSD.
Watanabe M; Nakamura Y; Michalak Z; Isobe N; Barro C; Leppert D; Matsushita T; Hayashi F; Yamasaki R; Kuhle J; Kira JI. Neurology. 2019.Serum GFAP Associates with Neurofilament Light and Disease Severity in Late Multiple Sclerosis
Airas, Laura; Hoegel, Heidi; Rissanen, Eero; Matilainen, Markus; Nylund, Marjo; Kuhle, Jens. Neurology. 2019.Serum glial fibrillary acidic protein (GFAP) and neurofilament light chain (NfL) as potential biomarkers for disease activity and disability in neuromyelitis optica spectrum disorders and multiple sclerosis
Watanabe, Mitsuru; Nakamura, Yuri; Michalak, Zuzanna; Hayashi, Fumie; Barro, Christian; Isobe, Noriko; Matsushita, Takuya; Yamasaki, Ryo; Kuhle, Jens; Kira, Jun-ichi. Multiple sclerosis (Houndmills, Basingstoke, England). 2019.Serum neurofilament dynamics predicts neurodegeneration and clinical progression in presymptomatic Alzheimer's disease.
Preische O; Schultz SA; Apel A; Kuhle J; Kaeser SA; Barro C; Gräber S; Kuder-Buletta E; LaFougere C; Laske C; Vöglein J; Levin J; Masters CL; Martins R; Schofield PR; Rossor MN; Graff-Radford NR; Salloway S; Ghetti B; Ringman JM; Noble JM; Chhatwal J; Goate AM; Benzinger TLS; Morris JC; Bateman RJ; Wang G; Fagan AM; McDade EM; Gordon BA; Jucker M; Dominantly Inherited Alzheimer Network. Nature Medicine. 2019.Serum Neurofilament Light (sNfL) for Disease Prognosis and Treatment Monitoring in Multiple Sclerosis Patients:Towards Implementation into Clinical Care
Calabresi, Peter A.; Kuhle, Jens; Arnold, Douglas L.; Kinkel, R. Philip; Kappos, Ludwig; Singh, Carol M.; Sangurdekar, Dipen; de Moor, Carl; Engle, Bob; Su, Ray; Deykin, Aaron; Fisher, Elizabeth; Sandrock, Alfred; Kieseier, Bernd C.; Rudick, Richard A.; Plavina, Tatiana. Neurology. 2019.Serum Neurofilament light chain (NfL) as outcome marker for intensive- care unit (ICU) patients and critical illness polyneuropathy (CIP)
Fisse, A. L.; Kuhle, J.; Michalak, Z.; Yoon, M-S.; Kappos, L.; Gold, R.; Pitarokoili, K.. European Journal of Neurology . 2019.Serum neurofilament light chain as a presymptomatic biomarker in multiple sclerosis
Bjornevik, K.; Munger, K. L.; Cortese, M.; Barro, C.; Healy, B. C.; Niebuhr, D. W.; Scher, A. I.; Kuhle, J.; Ascherio, A.. Multiple sclerosis (Houndmills, Basingstoke, England). 2019.Serum neurofilament light chain as a prognostic marker in postanoxic encephalopathy.
Disanto G; Prosperetti C; Gobbi C; Barro C; Michalak Z; Cassina T; Kuhle J; Casso G; Agazzi P. Epilepsy & behavior : E&B. 2019.Serum neurofilament light chain in chronic inflammatory demyelinating polyneuropathy.
van Lieverloo GGA; Wieske L; Verhamme C; Vrancken AFJ; van Doorn PA; Michalak Z; Barro C; van Schaik IN; Kuhle J; Eftimov F. JOURNAL OF THE PERIPHERAL NERVOUS SYSTEM. 2019.Serum neurofilament light chain in pediatric MS and other acquired demyelinating syndromes.
Wong YYM; Bruijstens AL; Barro C; Michalak Z; Melief MJ; Wierenga AF; van Pelt ED; Neuteboom RF; Kuhle J; Hintzen RQ. Neurology. 2019.Serum neurofilament light chain is a biomarker of acute and chronic neuronal damage in early multiple sclerosis.
Siller N; Kuhle J; Muthuraman M; Barro C; Uphaus T; Groppa S; Kappos L; Zipp F; Bittner S. Multiple sclerosis (Houndmills, Basingstoke, England). 2019.Serum neurofilament light chain levels and cognitive performance in multiple sclerosis: a longitudinal retrospective 5-year study
Jakimovski, Dejan; Zivadinov, Robert; Ramanathan, Murali; Hagemeier, Jesper; Weinstock-Guttman, Bianca; Tomic, Davorka; Kropshofer, Harald; Barro, Christian; Leppert, David; Yaldizli, Ozgur; Kuhle, Jens; Benedict, Ralph. Neurology. 2019.Serum neurofilament light chain levels are increased within three months of new gadolinium enhancing lesions in multiple sclerosis
Rosso, M.; Gonzalez, C.; Healy, B.; Saxena, S.; Paul, A.; Bjornevik, K.; Guttmann, C.; Bakshi, R.; Chitnis, T.; Weiner, H.; Kuhle, J.; Leppert, D.. Multiple sclerosis (Houndmills, Basingstoke, England). 2019.Serum neurofilament light chain levels associations with gray matter pathology: a 5-year longitudinal study.
Jakimovski D; Kuhle J; Ramanathan M; Barro C; Tomic D; Hagemeier J; Kropshofer H; Bergsland N; Leppert D; Dwyer MG; Michalak Z; Benedict RHB; Weinstock-Guttman B; Zivadinov R. Annals of Clinical and Translational Neurology. 2019.Serum Neurofilament Light Chain Levels Correlate with Disease Characteristics in Patients with Relapsing-Remitting Multiple Sclerosis from CARE-MS I
Kuhle, Jens; Daizadeh, Nadia; Barro, Christian; Michalak, Zuzanna; Leppert, David; Godin, Jean; Shankara, Srinivas; Samad, Tarek; Jacobs, Alan; Chung, Luke; Roesch, Nora; Kaiser, Carina; Havari, Evis; Kappos, Ludwig. Multiple sclerosis (Houndmills, Basingstoke, England). 2019.Serum neurofilament light chain levels predict thalamic volume loss in multiple sclerosis
Magon, S.; Schaedelin, S.; Barro, C.; Tsagkas, C.; Chakravarty, M.; Gaetano, L.; Naegelin, Y.; Benkert, P.; Amann, M.; Parmar, K.; Papadopoulou, A.; Wuerfel, J.; Yaldizli, O.; Oechtering, J.; Leppert, D.; Sprenger, T.; Kappos, L.; Granziera, C.; Kuhle, J.. Multiple sclerosis (Houndmills, Basingstoke, England). 2019.Serum neurofilament light levels in normal aging: associations with morphologic brain changes
Khalil, M.; Pirpamer, L.; Hofer, E.; Voortman, M.; Barro, C.; Ropele, S.; Enzinger, C.; Fazekas, F.; Schmidt, R.; Kuhle, J.. European Journal of Neurology . 2019.Serum neurofilaments levels are associated with blood brain barrier injury in early multiple sclerosis
Uher, T.; McComb, M.; Galkin, S.; Srpova, B.; Oechtering, J.; Barro, C.; Tyblova, M.; Havrdova, E. Kubala; Posova, H.; Horakova, D.; Kuhle, J.; Ramanathan, M.. Multiple sclerosis (Houndmills, Basingstoke, England). 2019.The association between serum neurofilament light chain, atrophied lesion volume and brain atrophy with disability progression in multiple sclerosis
Tavazzi, Eleonora; Ramanathan, Murali; Barro, Christian; Hagemeier, Jesper; Jakimovski, Dejan; Bergsland, Niels; Tomic, Davorka; Kropshofer, Harald; Leppert, David; Michalak, Zuzanna; Dwyer, Michael; Benedict, Ralph; Weinstock-Guttman, Bianca; Kuhle, Jens; Zivadinov, Robert. Neurology. 2019.The association between serum neurofilament light chain and OCT measures in multiple sclerosis
Hagemeier, Jesper; Tavazzi, Eleonora; Ramanathan, Murali; Jakimovski, Dejan; Bergsland, Niels; Tomic, Davorka; Kropshofer, Harald; Leppert, David; Michalak, Zuzanna; Dwyer, Michael; Benedict, Ralph; Weinstock-Guttman, Bianca; Kuhle, Jens; Zivadinov, Robert. Neurology. 2019.The Correlation of Blood Neurofilament Light Chain with Brain Atrophy is Partly Independent from Inflammation
Sormani, Maria Pia; Kappos, Ludwig; Haring, Dieter A.; Kropshofer, Harald; Barro, Christian; Leppert, David; Tomic, Davorka; Kuhle, Jens. Neurology. 2019.The Predictive Value of Neurofilament Light Chain Levels in Blood for Cognitive Impairment in Patients with Secondary Progressive Multiple Sclerosis
Kuhle, Jens; Kropshofer, Harald; Barro, Christian; Meinert, Rolf; Haring, Dieter; Leppert, David; Dahlke, Frank; Tomic, Davorka; Kappos, Ludwig. Neurology. 2019.A digitally facilitated citizen-science driven approach accelerates participant recruitment and increases study population diversity.
Puhan MA; Steinemann N; Kamm CP; Müller S; Kuhle J; Kurmann R; Calabrese P; Kesselring J; von Wyl V; Swiss Multiple Sclerosis Registry Smsr. Swiss medical weekly. 2018.An integral measure of serial neurofilament light chain assessments in blood is a predictor of long-term disability progression in relapsing-remitting multiple sclerosis
Kuhle, J.; Cohen, J.; Haring, D. A.; Kropshofer, H.; Leppert, D.; Tomic, D.; Kappos, L.. Multiple sclerosis (Houndmills, Basingstoke, England). 2018.Blood neurofilament light chain levels are elevated in paediatric patients with multiple sclerosis and reduced under disease-modifying treatment
Reinert, M. -C.; Kropshofer, H.; Barro, C.; Wuerfel, J.; Benkert, P.; Michalak, Z.; Brueck, W.; Huppke, P.; Tomic, D.; Leppert, D.; Kuhle, J.; Gaertner, J.. Multiple sclerosis (Houndmills, Basingstoke, England). 2018.Brain endothelial cell expression of SPARCL-1 is specific to chronic multiple sclerosis lesions and is regulated by inflammatory mediators in vitro.
Bridel C; Koel-Simmelink MJA; Peferoen L; Derada Troletti C; Durieux S; Gorter R; Nutma E; Gami P; Iacobaeus E; Brundin L; Kuhle J; Vrenken H; Killestein J; Piersma SR; Pham TV; De Vries HE; Amor S; Jimenez CR; Teunissen CE. Neuropathology and Applied Neurobiology. 2018.Central Slab versus Whole Brain to Measure Brain Atrophy in Multiple Sclerosis.
Ruberte E; Sinnecker T; Amann M; Gaetano L; Naegelin Y; Penner IK; Kuhle J; Derfuss T; Kappos L; Granziera C; Wuerfel J; Yaldizli Ö. European Neurology. 2018.Comparative analysis of natalizumab versus fingolimod as second-line treatment in relapsing-remitting multiple sclerosis.
Lorscheider J; Benkert P; Lienert C; Hänni P; Derfuss T; Kuhle J; Kappos L; Yaldizli Ö. Multiple sclerosis (Houndmills, Basingstoke, England). 2018.Dimethyl fumarate influences innate and adaptive immunity in multiple sclerosis
Diebold M.; Sievers C.; Bantug G.; Sanderson N.; Kappos L.; Kuhle J.; Lindberg R.L.P.; Derfuss T.. Journal of autoimmunity. 2018.Exploring the effect of vitamin D(3) supplementation on the anti-EBV antibody response in relapsing-remitting multiple sclerosis.
Rolf L; Muris AH; Mathias A; Du Pasquier R; Koneczny I; Disanto G; Kuhle J; Ramagopalan S; Damoiseaux J; Smolders J; Hupperts R. Multiple sclerosis (Houndmills, Basingstoke, England). 2018.Factors associated with time from first-symptoms to diagnosis and treatment initiation of Multiple Sclerosis in Switzerland.
Kaufmann M; Kuhle J; Puhan MA; Kamm CP; Chan A; Salmen A; Kesselring J; Calabrese P; Gobbi C; Pot C; Steinemann N; Rodgers S; von Wyl V; Swiss Multiple Sclerosis Registry (SMSR). Multiple sclerosis journal - experimental, translational and clinical. 2018.Higher Predictive Value Positive for MMA Than ACA MTM Eligibility Criteria Among Racial and Ethnic Minorities: An Observational Study.
Qiao Y; Spivey CA; Wang J; Shih YT; Wan JY; Kuhle J; Dagogo-Jack S; Cushman WC; Chisholm-Burns MA. INQUIRY-THE JOURNAL OF HEALTH CARE ORGANIZATION PROVISION AND FINANCING. 2018.Including Blood Neurofilament Light Chain in the NEDA Concept in Relapsing-Remitting Multiple Sclerosis Trials
Sormani, Maria Pia; Kappos, Ludwig; Haring, Dieter; Kropshofer, Harald; Barro, Christian; Leppert, David; Tomic, Davorka; Kuhle, Jens. Neurology. 2018.International multi-site analytical validation of the Simoa NF-light assay in human serum samples from multiple sclerosis patients
Kuhle, J.; Barro, C.; Hrusovsky, K.; Chang, L.; Jeromin, A.; Bridel, C.; Bar-Or, A.; Bittner, S.; Brueck, W.; Bielekova, B.; Chitnis, T.; Comi, G.; Comabella, M.; Arrambide, G.; Montalban, X.; Datwani, A.; Fluck, M.; Fox, R.; Freedman, M.; Furlan, R.; Gnanapavan, S.; Giovannoni, G.; Havari, E.; Khalil, M.; Leppert, D.; Kropshofer, H.; Valentin, M. A.; Oksenberg, J.; Piehl, F.; Plavina, T.; Sormani, M. P.; Lehmann, S.; Thouvenot, E.; Ziemssen, T.; Zipp, F.; Gross, C.; Wiendl, H.; Kappos, L.; Michalak, Z.; Blennow, K.; Zetterberg, H.; Teunissen, C.; Wilson, D.. Multiple sclerosis (Houndmills, Basingstoke, England). 2018.Long-term Prognosis of Disease Evolution and Evidence for Sustained Fingolimod Treatment Effect by Blood Neurofilament Light in RRMS Patients
Kuhle, Jens; Cohen, Jeffery A.; Kropshofer, Harald; Meinert, Rolf; Barro, Christian; Merschhemke, Martin; Haring, Dieter; Leppert, David; Tomic, Davorka; Kappos, Ludwig. Neurology. 2018.Multicenter evaluation of neurofilaments in early symptom onset amyotrophic lateral sclerosis.
Feneberg E; Oeckl P; Steinacker P; Verde F; Barro C; Van Damme P; Gray E; Grosskreutz J; Jardel C; Kuhle J; Koerner S; Lamari F; Amador MDM; Mayer B; Morelli C; Muckova P; Petri S; Poesen K; Raaphorst J; Salachas F; Silani V; Stubendorff B; Turner MR; Verbeek MM; Weishaupt JH; Weydt P; Ludolph AC; Otto M. Neurology. 2018.Neurofilament as Neuronal Injury Blood Marker in Preeclampsia.
Evers KS; Atkinson A; Barro C; Fisch U; Pfister M; Huhn EA; Lapaire O; Kuhle J; Wellmann S. Hypertension. 2018.Neurofilament Light Chain: Blood Biomarker of Neonatal Neuronal Injury.
Depoorter A; Neumann RP; Barro C; Fisch U; Weber P; Kuhle J; Wellmann S. Frontiers in Neurology. 2018.Neurofilament light chain is a useful biomarker in paediatric multiple sclerosis
Reinert, M. -C.; Barro, C.; Michalak, Z.; Brueck, W.; Huppke, P.; Kropshofer, H.; Tomic, D.; Leppert, D.; Kuhle, J.; Gaertner, J.. Multiple sclerosis (Houndmills, Basingstoke, England). 2018.Neurofilament light chain levels in pregnant multiple sclerosis patients: a prospective cohort study
Cuello, J. P.; Martinez Gines, M. L.; Lozano Ros, A.; Romero Delgado, F.; Garcia Dominguez, J. M.; Higueras, Y.; Meldana Rivera, A.; Garcia Tizon, S.; de Leon-Luis, J.; Ortega Abad, V.; Perez Perez, S.; Dominguez-Mozo, M. I.; Alvarez Lafuente, R.; Medina Heras, S.; Fernandez Velasco, J. I.; Tejeda-velarde, A.; Andres, C. de; Goicochea Briceno, H.; Kuhle, J.; Michalak, Z.; Barro, C.; Villar Guimerans, L. M.. Multiple sclerosis (Houndmills, Basingstoke, England). 2018.Neurofilament light chain predicts disease activity in relapsing-remitting MS.
Varhaug KN; Barro C; Bjørnevik K; Myhr KM; Torkildsen Ø; Wergeland S; Bindoff LA; Kuhle J; Vedeler C. Neurology(R) neuroimmunology & neuroinflammation. 2018.Neurofilament light chain serum levels correlate with 10-year MRI outcomes in multiple sclerosis.
Chitnis T; Gonzalez C; Healy BC; Saxena S; Rosso M; Barro C; Michalak Z; Paul A; Kivisakk P; Diaz-Cruz C; Sattarnezhad N; Pierre IV; Glanz BI; Tomic D; Kropshofer H; Häring D; Leppert D; Kappos L; Bakshi R; Weiner HL; Kuhle J. Annals of Clinical and Translational Neurology. 2018.Neurofilaments as biomarkers in neurological disorders.
Khalil M; Teunissen CE; Otto M; Piehl F; Sormani MP; Gattringer T; Barro C; Kappos L; Comabella M; Fazekas F; Petzold A; Blennow K; Zetterberg H; Kuhle J. Nature reviews. Neurology. 2018.NfL is a biomarker for adult-onset leukoencephalopathy with axonal spheroids and pigmented glia.
Hayer SN; Krey I; Barro C; Rössler F; Körtvelyessy P; Lemke JR; Kuhle J; Schöls L. Neurology. 2018.Normative values of serum neurofilament light levels
Khalil, M.; Pirpamer, L.; Hofer, E.; Voortman, M. M.; Hallwirth, F.; Barro, C.; Fazekas, F.; Schmidt, R.; Kuhle, J.. Multiple sclerosis (Houndmills, Basingstoke, England). 2018.Plasma neurofilament light levels are associated with risk of developing sustained disability in multiple sclerosis
Manouchehrinia, A.; Delcoigne, B.; Barro, C.; Michalak, Z.; Alfredsson, L.; Kappos, L.; Piehl, F.; Olsson, T.; Kuhle, J.; Kockum, I.. Multiple sclerosis (Houndmills, Basingstoke, England). 2018.Prodromal symptoms of multiple sclerosis in primary care.
Disanto G; Zecca C; MacLachlan S; Sacco R; Handunnetthi L; Meier UC; Simpson A; McDonald L; Rossi A; Benkert P; Kuhle J; Ramagopalan SV; Gobbi C. Annals of Neurology. 2018.Recurrence of disease activity after fingolimod discontinuation - observations in a real-world cohort with 433 multiple sclerosis patients.
Cerda, N.; Nagy, S.; Sinnecker, T.; Wurfel, J.; Kuhle, J.; Yaldizli, O.; Kappos, L.; Derfuss, T.; Decard, B. F.. Multiple sclerosis (Houndmills, Basingstoke, England). 2018.Serum glial fibrillary acidic protein (GFAP) and neurofilament light chain (NfL) in neuromyelitis optica spectrum disorders.
Watanabe, M.; Nakamura, Y.; Michalak, Z.; Hayashi, F.; Barro, C.; Isobe, N.; Matsushita, T.; Yamasaki, R.; Kuhle, J.; Kira, J-I. Multiple sclerosis (Houndmills, Basingstoke, England). 2018.Serum light-chain neurofilament, a brain lesion marker, correlates with CHA2DS2-VASc score among patients with atrial fibrillation: a cross-sectional study
Aeschbacher, S.; Kuhle, J.; Benkert, P.; Rodondi, N.; Mueller, A.; Ammann, P.; Auricchio, A.; Shah, D.; Sticherling, C.; Ehret, G.; Roten, L.; Kuhne, M.; Osswald, S.; Conen, D.; Bonati, L.. European Heart Journal. 2018.Serum neurofilament as a predictor of disease worsening and brain and spinal cord atrophy in multiple sclerosis.
Barro C; Benkert P; Disanto G; Tsagkas C; Amann M; Naegelin Y; Leppert D; Gobbi C; Granziera C; Yaldizli Ö; Michalak Z; Wuerfel J; Kappos L; Parmar K; Kuhle J. Brain. 2018.Serum neurofilament light: A biomarker of neuroaxonal injury after ischemic stroke.
Tiedt S; Duering M; Barro C; Kaya AG; Boeck J; Bode FJ; Klein M; Dorn F; Gesierich B; Kellert L; Ertl-Wagner B; Goertler MW; Petzold GC; Kuhle J; Wollenweber FA; Peters N; Dichgans M. Neurology. 2018.Serum neurofilament light (NfL) for disease prognosis and treatment monitoring in multiple sclerosis patients: is it ready for implementation into clinical care?.
Calabresi, P.; Kuhle, J.; Arnold, D. L.; Singh, C. M.; Kinkel, R. P.; Kappos, L.; Sangurdekar, D.; de Moor, C.; Engle, B.; Su, R.; Deykin, A.; Fisher, E.; Sandrock, A.; Kieseier, B. C.; Rudick, R. A.; Plavina, T.. Multiple sclerosis (Houndmills, Basingstoke, England). 2018.Serum neurofilament light chain: a biomarker of neuronal injury in vasculitic neuropathy.
Bischof A; Manigold T; Barro C; Heijnen I; Berger CT; Derfuss T; Kuhle J; Daikeler T. Annals of the rheumatic diseases. 2018.Serum neurofilament light chain in chronic inflammatory demyelinating polyneuropathy
van Lieverloo, Gwen; Wieske, Luuk; Verhamme, Camiel; Michalak, Zuzanna; Barro, Christian; van Schaik, Ivo; Kuhle, Jens; Eftimov, Filip. JOURNAL OF THE PERIPHERAL NERVOUS SYSTEM. 2018.Serum neurofilament light chain in patients with acute cerebrovascular events
De Marchis G.M.; Katan M.; Barro C.; Fladt J.; Traenka C.; Seiffge D.J.; Hert L.; Gensicke H.; Disanto G.; Sutter R.; Peters N.; Sarikaya H.; Goeggel-Simonetti B.; El-Koussy M.; Engelter S.; Lyrer P.A.; Christ-Crain M.; Arnold M.; Kuhle J.; Bonati L.H.. European Journal of Neurology. 2018.Serum neurofilament light chain in pediatric acquired demyelinating syndromes
Wong, Y. Y. M.; Bruijstens, A.; van Pelt, D.; Barro, C.; Michalak, Z.; Neuteboom, R. F.; Kuhle, J.; Hintzen, R. Q.. Multiple sclerosis (Houndmills, Basingstoke, England). 2018.Serum neurofilament light chain is increased in hereditary spastic paraplegias.
Wilke C; Rattay TW; Hengel H; Zimmermann M; Brockmann K; Schöls L; Kuhle J; Schüle R; Synofzik M. Annals of Clinical and Translational Neurology. 2018.Serum neurofilament light chain levels and cross-sectional and longitudinal deep gray matter changes: 5-year longitudinal MRI study
Kuhle, J.; Jakimovski, D.; Barro, C.; Ramanathan, M.; Hagemeier, J.; Bergsland, N.; Tomic, D.; Kropshofer, H.; Leppert, D.; Michalak, Z.; Dwyer, M. G.; Benedict, R. H. B.; Weinstock-Guttman, B.; Zivadinov, R.. Multiple sclerosis (Houndmills, Basingstoke, England). 2018.Serum Neurofilament Light Chain Levels Are Related to Small Vessel Disease Burden.
Duering M; Konieczny MJ; Tiedt S; Baykara E; Tuladhar AM; Leijsen EV; Lyrer P; Engelter ST; Gesierich B; Achmüller M; Barro C; Adam R; Ewers M; Dichgans M; Kuhle J; de Leeuw FE; Peters N. Journal of stroke. 2018.Serum neurofilament light is increased in multiple system atrophy of cerebellar type and in repeat-expansion spinocerebellar ataxias: a pilot study.
Wilke C; Bender F; Hayer SN; Brockmann K; Schöls L; Kuhle J; Synofzik M. Journal of Neurology. 2018.Siponimod Reduces Neurofilament Light Chain Blood Levels in Secondary Progressive Multiple Sclerosis Patients
Kuhle, Jens; Kropshofer, Harald; Barro, Christian; Meinert, Rolf; Haring, Dieter A.; Leppert, David; Tomic, Davorka; Dahlke, Frank; Kappos, Ludwig. Neurology. 2018.The disease burden of Multiple Sclerosis from the individual and population perspective: Which symptoms matter most?
Barin L; Salmen A; Disanto G; Babačić H; Calabrese P; Chan A; Kamm CP; Kesselring J; Kuhle J; Gobbi C; Pot C; Puhan MA; von Wyl V; Swiss Multiple Sclerosis Registry (SMSR). Multiple Sclerosis and Related Disorders. 2018.The Swiss Multiple Sclerosis Registry (SMSR): study protocol of a participatory, nationwide registry to promote epidemiological and patient-centered MS research.
Steinemann N; Kuhle J; Calabrese P; Kesselring J; Disanto G; Merkler D; Pot C; Ajdacic-Gross V; Rodgers S; Puhan MA; von Wyl V; Swiss Multiple Sclerosis Registry. BMC neurology. 2018.Value of serum neurofilament light chain levels as a biomarker of suboptimal treatment response in MS clinical practice.
Yaldizli, O.; Barro, C.; Michalak, Z.; Vehoff, J.; Lascano, A. M.; Disanto, G.; Salmen, A.; Derfuss, T.; Granziera, C.; Achtnichts, L.; Findling, O.; Nedeltchev, K.; Kamm, C. P.; Pot, C.; Schluep, M.; Du Pasquier, R.; von Wyl, V.; Wuerfel, J.; Vallejo, V.; Chan, A.; Zecca, C.; Gobbi, C.; Lalive, P. H.; Mueller, S.; Kappos, L.; Benkert, P.; Kuhle, J.. Multiple sclerosis (Houndmills, Basingstoke, England). 2018.[Real-world evidence : Benefits and limitations in multiple sclerosis research].
Ziemssen T; Rothenbacher D; Kuhle J; Berger T. Nervenarzt. 2017.Anti-inflammatory disease modifying treatment and disability progression in primary progressive multiple sclerosis
Lorscheider, J.; Kuhle, J.; Izquierdo, G.; Lugaresi, A.; Havrdova, E.; Horakova, D.; Hupperts, R.; Duquette, P.; Girard, M.; Prat, A.; Grand'Maison, F.; Grammond, P.; Sola, P.; Ferraro, D.; Trojano, M.; Ramo-Tello, C.; Lechner-Scott, J.; Pucci, E.; Slee, M.; Van Pesch, V.; Van der Walt, A.; Butzkueven, H.; Kappos, L.; Kalincik, T.. Multiple sclerosis (Houndmills, Basingstoke, England). 2017.Autoantibodies to neurofilament light protein as a potential biomarker of treatment response and disease progression in multiple sclerosis
Puentes, F.; Giovannoni, G.; Kuhle, J.. Multiple sclerosis (Houndmills, Basingstoke, England). 2017.Biomarker for progressive multiple sclerosis: cross-sectional relationship between disability, multimodal evoked potentials and serum neurofilament light chain in a multicenter study
Hardmeier, M.; Kuhle, J.; Schlaeger, R.; Lascano, A. M.; Toffolet, L.; Gobbi, C.; Lalive, P. H.; Kappos, L.; Fuhr, P.. Multiple sclerosis (Houndmills, Basingstoke, England). 2017.Blood NfL as a potential endpoint in Phase 2 clinical studies in relapsing-remitting multiple sclerosis
Sormani, M. P.; Haring, D. A.; Kropshofer, H.; Leppert, D.; Barro, C.; Kappos, L.; Tomic, D.; Kuhle, J.. Multiple sclerosis (Houndmills, Basingstoke, England). 2017.Comparison between central and whole brain atrophy in multiple sclerosis measured by structural image evaluation using normalization of atrophy (SIENA)
Sinnecker, T.; Ruberte, E.; Amann, M.; Naegelin, Y.; Radue, E. W.; Penner, I. K.; Kuhle, J.; Derfuss, T.; Stippich, C.; Kappos, L.; Wuerfel, J.; Yaldizli, O.. Multiple sclerosis (Houndmills, Basingstoke, England). 2017.Consensus guidelines for lumbar puncture in patients with neurological diseases.
Engelborghs S; Niemantsverdriet E; Struyfs H; Blennow K; Brouns R; Comabella M; Dujmovic I; van der Flier W; Frölich L; Galimberti D; Gnanapavan S; Hemmer B; Hoff E; Hort J; Iacobaeus E; Ingelsson M; Jan de Jong F; Jonsson M; Khalil M; Kuhle J; Lleó A; de Mendonça A; Molinuevo JL; Nagels G; Paquet C; Parnetti L; Roks G; Rosa-Neto P; Scheltens P; Skårsgard C; Stomrud E; Tumani H; Visser PJ; Wallin A; Winblad B; Zetterberg H; Duits F; Teunissen CE. Alzheimer's & dementia (Amsterdam, Netherlands). 2017.Cytometry by Time of Flight (CyTOF) shows an increase of T follicular helper-like cells in the CSF of MS patients
Sanderson, N.; Johansson, D.; Rauld, C.; Raad, L.; Kappos, L.; Kuhle, J.; Carballido, J.; Derfuss, T.. Multiple sclerosis (Houndmills, Basingstoke, England). 2017.Data quality evaluation for observational multiple sclerosis registries.
Kalincik T; Kuhle J; Pucci E; Rojas JI; Tsolaki M; Sirbu CA; Slee M; Butzkueven H; MSBase Scientific Leadership Group and MSBase Study Group. Multiple sclerosis (Houndmills, Basingstoke, England). 2017.Diagnostic and prognostic significance of neurofilament light chain NF-L, but not progranulin and S100B, in the course of amyotrophic lateral sclerosis: Data from the German MND-net.
Steinacker P; Huss A; Mayer B; Grehl T; Grosskreutz J; Borck G; Kuhle J; Lulé D; Meyer T; Oeckl P; Petri S; Weishaupt J; Ludolph AC; Otto M. Amyotrophic lateral sclerosis & frontotemporal degeneration. 2017.Diagnostic and prognostic value of plasma light-chain neurofilaments in acute cerebrovascular events - a prospective cohort study
de Marchis, G. M.; Katan, M.; Barro, C.; Buhl, D.; Traenka, C.; Seiffge, D. J.; Hert, L.; Gensicke, H.; Disanto, G.; Sutter, R.; Peters, N.; Sarikaya, H.; Goeggel-Simonetti, B.; El-Koussy, M.; Engelter, S. T.; Lyrer, P. A.; Christ-Crain, M.; Arnold, M.; Kuhle, J.; Bonati, L.. European Journal of Neurology. 2017.Epstein-Barr-negative MS: a true phenomenon?
Dobson R; Kuhle J; Middeldorp J; Giovannoni G. Neurology(R) neuroimmunology & neuroinflammation. 2017.Fingolimod significantly lowers neurofilament light chain blood levels in relapsing-remitting multiple sclerosis patients as compared with interferon beta-1a or placebo
Kuhle, J.; Barro, C.; Kappos, L.; Meinert, R.; Dahlke, F.; Kropshofer, H.; Tomic, D.; Leppert, D.. European Journal of Neurology. 2017.Fingolimod vs. dimethyl fumarate in relapsing-remitting multiple sclerosis: propensity score matched comparison in a large observational data set
Lorscheider, J.; Benkert, P.; Lienert, C.; Hanni, P.; Schmid, J.; Derfuss, T.; Kuhle, J.; Kappos, L.; Yaldizli, O.. Multiple sclerosis (Houndmills, Basingstoke, England). 2017.Fluid biomarker and electrophysiological outcome measures for progressive MS trials.
Barro C; Leocani L; Leppert D; Comi G; Kappos L; Kuhle J. Multiple sclerosis (Houndmills, Basingstoke, England). 2017.Inflammatory and Neuronal Biomarkers Associated With Retinal Thinning in Pediatric HIV.
Blokhuis C; Doeleman S; Cohen S; Demirkaya N; Scherpbier HJ; Kootstra NA; Kuhle J; Teunissen CE; Verbraak FD; Pajkrt D. Investigative ophthalmology & visual science. 2017.Kappa free light chains: an automated alternative to oligoclonal bands for CIS and MS diagnosis?
Leurs, C. E.; Twaalfhoven, H. A. M.; Witte, B. I.; van Pesch, V.; Dujmovic, I.; Drulovic, J.; Castellazzi, M.; Bellini, T.; Pugliatti, M.; Kuhle, J.; Villar, L. M.; Alvarez Cermeno, J. C.; Alvarez-Lafuente, R.; Hegen, H.; Deisenhammer, F.; Thouvenot, E.; Comabella, M.; Montalban, X.; Vecsei, L.; Rajda, C.; Galimberti, D.; Altintas, A.; Rejdak, K.; Frederiksen, J. L.; Pihl-Jensen, G.; Jensen, P. E.; Khalil, M.; Voortman, M. M.; Fazekas, F.; Saiz, A.; La Puma, D.; Vercammen, M.; Vanopdenbosch, L.; Uitdehaag, B. M. J.; Killestein, J.; Bridel, C.; Teunissen, C.. Multiple sclerosis (Houndmills, Basingstoke, England). 2017.Lymphocyte recovery in real life clinical practice after discontinuation of fingolimod in patients with multiple sclerosis
Nagy, S.; Kuhle, J.; Kappos, L.; Derfuss, T.. Multiple sclerosis (Houndmills, Basingstoke, England). 2017.Lymphocyte recovery in real life clinical practice after discontinuation of fingolimod in patients with multiple sclerosis
Nagy, S.; Kuhle, J.; Kappos, L.; Derfuss, T.. Multiple sclerosis (Houndmills, Basingstoke, England). 2017.Neurofilament light chain in human blood is a predictor of disease worsening in relapsing-remitting multiple sclerosis
Kuhle, J.; Kropshofer, H.; Haring, D. A.; Barro, C.; Kappos, L.; Leppert, D.; Tomic, D.. Multiple sclerosis (Houndmills, Basingstoke, England). 2017.PARP-1 deregulation in MS
Meira, M.; Sievers, C.; Hoffmann, F.; Derfuss, T.; Haghikia, A.; Kuhle, J.; Kappos, L.; Lindberg, R. L. P.. Multiple sclerosis (Houndmills, Basingstoke, England). 2017.Prodromal symptoms of multiple sclerosis in primary care: a case-control study using the UK Clinical Practice Research Datalink (CPRD)
Disanto, G.; MacLachlan, S.; Zecca, C.; Handunnetthi, L.; Sacco, R.; Meier, U.; Benkert, P.; Simpson, A.; McDonald, L.; Rossi, A.; Kuhle, J.; Ramagopalan, S. V.; Gobbi, C.. Multiple sclerosis (Houndmills, Basingstoke, England). 2017.Reduced Plasma Levels of 25-Hydroxycholesterol and Increased Cerebrospinal Fluid Levels of Bile Acid Precursors in Multiple Sclerosis Patients.
Crick PJ; Griffiths WJ; Zhang J; Beibel M; Abdel-Khalik J; Kuhle J; Sailer AW; Wang Y. Molecular Neurobiology. 2017.Serum neurofilament is associated with progression of brain atrophy and disability in early MS.
Kuhle J; Nourbakhsh B; Grant D; Morant S; Barro C; Yaldizli Ö; Pelletier D; Giovannoni G; Waubant E; Gnanapavan S. Neurology. 2017.Serum Neurofilament light: A biomarker of neuronal damage in multiple sclerosis.
Disanto G; Barro C; Benkert P; Naegelin Y; Schädelin S; Giardiello A; Zecca C; Blennow K; Zetterberg H; Leppert D; Kappos L; Gobbi C; Kuhle J; Swiss Multiple Sclerosis Cohort Study Group. Annals of Neurology. 2017.Serum neurofilament light chain as a biomarker for acute and chronic neuronal damage in early relapsing-remitting multiple sclerosis
Siller, N.; Kuhle, J.; Uphaus, T.; Barro, C.; Muthuraman, M.; Kappos, L.; Groppa, S.; Zipp, F.; Bittner, S.. Multiple sclerosis (Houndmills, Basingstoke, England). 2017.Serum Neurofilament light chain as a predictor of long-term outcomes in patients with CIS in the BENEFIT 11 trial
Kuhle, J.; Barro, C.; Edan, G.; Freedman, M. S.; Hartung, H-P.; Montalban, X.; Barkhof, F.; Fox, E. J.; Hemmer, B.; Schippling, S.; Koelbach, R.; Wicklein, E-M.; Kappos, L.. Multiple sclerosis (Houndmills, Basingstoke, England). 2017.Serum neurofilament light chain correlates with disease activity and predicts clinical and MRI outcomes in MS
Barro, C.; Benkert, P.; Grobke, S.; Naegelin, Y.; Disanto, G.; Amann, M.; Magon, S.; Derfuss, T.; Yaldizli, O.; Parmar, K.; Wuerfel, J.; Kappos, L.; Kuhle, J.. Multiple sclerosis (Houndmills, Basingstoke, England). 2017.Serum neurofilament light chain predicts disease activity in relapsing remitting multiple sclerosis
Varhaug, K.; Barro, C.; Bjornevik, K.; Torkildsen, O.; Wergeland, S.; Bindoff, L. A.; Kuhle, J.; Vedeler, C. A.. Multiple sclerosis (Houndmills, Basingstoke, England). 2017.Serum neurofilament light chain protein: A promising biomarker for lacunar stroke and cerebral small vessel disease
Gattringer, T.; Pinter, D.; Enzinger, C.; Kneihsl, M.; Fandler, S.; Pichler, A.; Barro, C.; Groebke, S.; Voortman, M.; Seifert-Held, T.; Pirpamer, L.; Hofer, E.; Ropele, S.; Schmidt, R.; Kuhle, J.; Fazekas, F.; Khalil, M.. European Journal of Neurology. 2017.Serum neurofilament light is sensitive to active cerebral small vessel disease.
Gattringer T; Pinter D; Enzinger C; Seifert-Held T; Kneihsl M; Fandler S; Pichler A; Barro C; Gröbke S; Voortman M; Pirpamer L; Hofer E; Ropele S; Schmidt R; Kuhle J; Fazekas F; Khalil M. Neurology. 2017.Vitamin D3 supplementation reduces antibody titers against the Epstein-Barr Virus nuclear antigen 1 (EBNA-1) in relapsing remitting multiple sclerosis
Rolf, L.; Muris, A-H.; Mathias, A.; Du Pasquier, R.; Koneczny, I.; Disanto, G.; Kuhle, J.; Damoiseaux, J.; Smolders, J.; Hupperts, R. M.. European Journal of Neurology. 2017.A 10-year follow-up of the European multicenter trial of interferon β-1b in secondary-progressive multiple sclerosis.
Kuhle J; Hardmeier M; Disanto G; Gugleta K; Ecsedi M; Lienert C; Amato MP; Baum K; Buttmann M; Bayas A; Brassat D; Brochet B; Confavreux C; Edan G; Färkkilä M; Fredrikson S; Frontoni M; D'Hooghe M; Hutchinson M; De Keyser J; Kieseier BC; Kümpfel T; Rio J; Polman C; Roullet E; Stolz C; Vass K; Wandinger KP; Kappos L; European Long-term Follow-up Study Group in Interferon β-1b in Secondary-progressive Multiple Sclerosis. Multiple sclerosis (Houndmills, Basingstoke, England). 2016.Anti-KIR4.1 antibodies do not differentiate multiple sclerosis patients from controls
Proebstel, Anne-Katrin; Kuhle, Jens; Lecourt, Anne-Catherine; Vock, Isabelle; Sanderson, Nicholas; Kappos, Ludwig; Derfuss, Tobias. Neurology. 2016.Association of Serum Neurofilament Light Chain with Cognitive and Disability Measures in Patients with Very Early MS: A Longitudinal Study
Nourbakhsh, Bardia; Gnanapavan, Sharmilee; Giovannoni, Gavin; Julian, Laura; Spain, Rebecca; Kuhle, Jens; Waubant, Emmanuelle. Neurology. 2016.Blood neurofilament light chain levels are elevated in multiple sclerosis and correlate with disease activity.
Kuhle, J.; Barro, C.; Brachat, A. H.; Valentin, M. -A.; Hillenbrand, R.; Kropshofer, H.; Kappos, L.; Dahlke, F.. Multiple sclerosis (Houndmills, Basingstoke, England). 2016.Comment: "If you can't measure it, you can't improve it" (Lord Kelvin).
Kuhle J. Neurology. 2016.Comparison of three analytical platforms for quantification of the neurofilament light chain in blood samples: ELISA, electrochemiluminescence immunoassay and Simoa.
Kuhle J; Barro C; Andreasson U; Derfuss T; Lindberg R; Sandelius Å; Liman V; Norgren N; Blennow K; Zetterberg H. Clinical chemistry and laboratory medicine. 2016.Consensus Guidelines for CSF and Blood Biobanking for CNS Biomarker Studies (vol 73, pg 1914, 2009)
Teunissen,Charlotte E; Tumani,Hayrettin; Bennett,Jeffrey L; Berven,Frode S; Brundin,Lou; Comabella,Manuel; Franciotta,Diego; Federiksen,Jette L; Fleming,John O; Furlan,Roberto; Hintzen,Rogier Q; Hughes,Steve G; Jimenez,Connie R; Johnson,Michael H; Killestein,Joep; Krasulova,Eva; Kuhle,Jens; Magnone,Maria-Chiara; Petzold,Axel; Rajda,Cecilia; Rejdak,Konrad; Schmidt,Hollie K; van Pesch,Vincent; Waubant,Emmanuelle; Wolf,Christian; Deisenhammer,Florian; Giovannoni,Gavin; Hemmer,Bernhard. Mult Scler Int. 2016.High sensitivity serum neurofilament-light chain measurements correlate with disease activity and disability in multiple sclerosis and are reduced after immunomodulatory treatment intervention.
Barro, C.; Derfuss, T.; Nagelin, Y.; Benkert, P.; Schadelin, S.; Yaldizli, O.; Achtnichts, L.; Nedeltchev, K.; Kamm, C. P.; Salmen, A.; Lalive, P. H.; Schluep, M.; Du Pasquier, R.; Muller, S.; Vehoff, J.; Norgren, N.; Zecca, C.; Disanto, G.; Gobbi, C.; Kappos, L.; Kuhle, J.. Multiple sclerosis (Houndmills, Basingstoke, England). 2016.Lateral Ventricle Volume change is associated with neurological and cognitive disability in multiple sclerosis: a 5-years follow-up study using an automated lateral ventricle segmentation algorithm
Ruberte, E.; Amann, M.; Naegelin, Y.; Penner, I. K.; Pardini, M.; Kuhle, J.; Derfuss, T.; Stippich, C.; Kappos, L.; Wuerfel, J.; Yaldizli, O.. Multiple sclerosis (Houndmills, Basingstoke, England). 2016.Lower relapse rates with natalizumab as compared with fingolimod as second-line treatment in relapsing-remitting multiple sclerosis
Lienert, C.; Benkert, P.; Beer, S.; Hanni, P.; Pardini, M.; D'Souza, M.; Derfuss, T.; Kuhle, J.; Kappos, L.; Yaldizli, O.. Multiple sclerosis (Houndmills, Basingstoke, England). 2016.Multiple Sclerosis and Antibodies against KIR4.1.
Pröbstel AK; Kuhle J; Lecourt AC; Vock I; Sanderson NS; Kappos L; Derfuss T. New England Journal of Medicine. 2016.Natalizumab-induced POU2AF1/Spi-B upregulation: A possible route for PML development.
Meira M; Sievers C; Hoffmann F; Haghikia A; Rasenack M; Décard BF; Kuhle J; Derfuss T; Kappos L; Lindberg RL. Neurology(R) neuroimmunology & neuroinflammation. 2016.Neurofilament levels as biomarkers in asymptomatic and symptomatic familial amyotrophic lateral sclerosis.
Weydt P; Oeckl P; Huss A; Müller K; Volk AE; Kuhle J; Knehr A; Andersen PM; Prudlo J; Steinacker P; Weishaupt JH; Ludolph AC; Otto M. Annals of Neurology. 2016.Neurofilament light chain, progranulin, and S-100B in longitudinal serum samples of patients with amyotrophic lateral sclerosis
Steinacker, P.; Huss, A.; Mayer, B.; Oeckl, P.; Lule, D.; Weishaupt, J.; Kuhle, J.; Meyer, T.; Petri, S.; Ludolph, A. C.; Otto, M.. Journal of neurochemistry. 2016.Neurofilament light chain: a biomarker for disease onset and survival in genetic frontotemporal dementia
Meeter, L.; Dopper, E.; Jiskoot, L.; Sanchez-Valle, R.; Graff, C.; Benussi, L.; Ghidoni, R.; Pijnenburg, Y.; Borroni, B.; Galimberti, D.; Laforce, R. J.; Masellis, M.; Vandenberghe, R.; Le Ber, I.; Otto, M.; van Minkelen, R.; Papma, J.; Rombouts, S.; Balasa, M.; Oijerstedt, L.; Jelic, V.; Cash, D.; Harding, S.; Cardoso, M. J.; Ourselin, S.; Dick, K.; Rossor, M.; Binetti, G.; Padovani, A.; Scarpini, E.; Fenoglio, C.; Tartaglia, C.; Lamari, F.; Barro, C.; Kuhle, J.; Rohrer, J.; Teunissen, C.; van Swieten, J.. Journal of neurochemistry. 2016.Neurofilament light chain: a biomarker for genetic frontotemporal dementia.
Meeter LH; Dopper EG; Jiskoot LC; Sanchez-Valle R; Graff C; Benussi L; Ghidoni R; Pijnenburg YA; Borroni B; Galimberti D; Laforce RJ; Masellis M; Vandenberghe R; Ber IL; Otto M; van Minkelen R; Papma JM; Rombouts SA; Balasa M; Öijerstedt L; Jelic V; Dick KM; Cash DM; Harding SR; Jorge Cardoso M; Ourselin S; Rossor MN; Padovani A; Scarpini E; Fenoglio C; Tartaglia MC; Lamari F; Barro C; Kuhle J; Rohrer JD; Teunissen CE; van Swieten JC. Annals of Clinical and Translational Neurology. 2016.Neurofilament Light Chain Determination from Peripheral Blood Samples.
Limberg M; Disanto G; Barro C; Kuhle J. Methods in Molecular Biology. 2016.Neurofilament Light Chain in Blood and CSF as Marker of Disease Progression in Mouse Models and in Neurodegenerative Diseases.
Bacioglu M; Maia LF; Preische O; Schelle J; Apel A; Kaeser SA; Schweighauser M; Eninger T; Lambert M; Pilotto A; Shimshek DR; Neumann U; Kahle PJ; Staufenbiel M; Neumann M; Maetzler W; Kuhle J; Jucker M. Neuron. 2016.Neurofilament Light Chain in Blood and CSF as Marker of Disease Progression in Mouse Models and in Neurodegenerative Diseases.
Bacioglu M; Maia LF; Preische O; Schelle J; Apel A; Kaeser SA; Schweighauser M; Eninger T; Lambert M; Pilotto A; Shimshek DR; Neumann U; Kahle PJ; Staufenbiel M; Neumann M; Maetzler W; Kuhle J; Jucker M. Neuron. 2016.Neurofilament light chain in FTD is elevated not only in cerebrospinal fluid, but also in serum.
Wilke C; Preische O; Deuschle C; Roeben B; Apel A; Barro C; Maia L; Maetzler W; Kuhle J; Synofzik M. Journal of Neurology, Neurosurgery and Psychiatry. 2016.Neurofilament light chain level is a weak risk factor for the development of MS.
Arrambide G; Espejo C; Eixarch H; Villar LM; Alvarez-Cermeño JC; Picón C; Kuhle J; Disanto G; Kappos L; Sastre-Garriga J; Pareto D; Simon E; Comabella M; Río J; Nos C; Tur C; Castilló J; Vidal-Jordana A; Galán I; Arévalo MJ; Auger C; Rovira A; Montalban X; Tintore M. Neurology. 2016.Neurofilament results for the phase II neuroprotection study of phenytoin in optic neuritis
Gnanapavan, S.; Grant, D.; Raftopoulos, R.; Hickman, S.; Altmann, D.; Barro, C.; Blennow, K.; Zetterberg, H.; Kapoor, R.; Giovannoni, G.; Kuhle, J.. Multiple sclerosis (Houndmills, Basingstoke, England). 2016.Neurofilaments in blood and CSF for diagnosis and prediction of onset in Creutzfeldt-Jakob disease.
Steinacker P; Blennow K; Halbgebauer S; Shi S; Ruf V; Oeckl P; Giese A; Kuhle J; Slivarichova D; Zetterberg H; Otto M. Scientific Reports. 2016.Neurometabolite Alterations Associated With Cognitive Performance in Perinatally HIV-Infected Children.
Van Dalen YW; Blokhuis C; Cohen S; Ter Stege JA; Teunissen CE; Kuhle J; Kootstra NA; Scherpbier HJ; Kuijpers TW; Reiss P; Majoie CBLM; Caan MWA; Pajkrt D. Medicine. 2016.Serum neurofilament light chain in early relapsing remitting MS is increased and correlates with CSF levels and with MRI measures of disease severity.
Kuhle J; Barro C; Disanto G; Mathias A; Soneson C; Bonnier G; Yaldizli Ö; Regeniter A; Derfuss T; Canales M; Schluep M; Du Pasquier R; Krueger G; Granziera C. Multiple sclerosis (Houndmills, Basingstoke, England). 2016.Serum neurofilament light chain levels are associated with cognitive and disability measures in patients with very early MS: a longitudinal study
Nourbakhsh, Bardia; Gnanapavan, Sharmilee; Giovannoni, Gavin; Julian, Laura; Spain, Rebecca I.; Kuhle, Jens; Waubant, Emmanuelle. Multiple sclerosis (Houndmills, Basingstoke, England). 2016.Serum neurofilament light chain levels are increased in patients with a clinically isolated syndrome.
Disanto G; Adiutori R; Dobson R; Martinelli V; Dalla Costa G; Runia T; Evdoshenko E; Thouvenot E; Trojano M; Norgren N; Teunissen C; Kappos L; Giovannoni G; Kuhle J; International Clinically Isolated Syndrome Study Group. Journal of Neurology, Neurosurgery and Psychiatry. 2016.Serum neurofilament light chain levels in MS: a promising biomarker of clinical and subclinical disease severity.
Disanto, G.; Barro, C.; Giardiello, A.; Gobbi, C.; Zecca, C.; Kuhle, J.. Multiple sclerosis (Houndmills, Basingstoke, England). 2016.Severe exacerbation of relapsing-remitting multiple sclerosis after G-CSF therapy.
Rust H; Kuhle J; Kappos L; Derfuss T. Neurology(R) neuroimmunology & neuroinflammation. 2016.Systemic inflammatory response and neuromuscular involvement in amyotrophic lateral sclerosis.
Lu CH; Allen K; Oei F; Leoni E; Kuhle J; Tree T; Fratta P; Sharma N; Sidle K; Howard R; Orrell R; Fish M; Greensmith L; Pearce N; Gallo V; Malaspina A. Neurology(R) neuroimmunology & neuroinflammation. 2016.The association between olfactory bulb volume, cognitive dysfunction, physical disability and depression in multiple sclerosis
Yaldizli O.; Penner I.-K.; Yonekawa T.; Naegelin Y.; Kuhle J.; Pardini M.; Chard D.T.; Stippich C.; Kira J.-I.; Bendfeldt K.; Amann M.; Radue E.-W.; Kappos L.; Sprenger T.. European Journal of Neurology. 2016.The association between retinal nerve fibre layer thickness and N-acetyl aspartate levels in multiple sclerosis brain normal-appearing white matter: a longitudinal study using magnetic resonance spectroscopy and optical coherence tomography
Pardini, M; Botzkowski, D; Müller, S; Vehoff, J; Kuhle, J; Ruberte, E; Würfel, J; Gass, A; Valmaggia, C; Tettenborn, B; Putzki, N; Yaldizli, Ö. European Journal of Neurology. 2016.The Swiss Multiple Sclerosis Cohort-Study (SMSC): A prospective Swiss wide investigation of key phases in disease evolution and new treatment options
Disanto G.; Benkert P.; Lorscheider J.; Mueller S.; Vehoff J.; Zecca C.; Ramseier S.; Achtnichts L.; Findling O.; Nedeltchev K.; Radue E.-W.; Sprenger T.; Stippich C.; Derfuss T.; Louvion J.-F.; Kamm C.P.; Mattle H.P.; Lotter C.; Du Pasquier R.; Schluep M.; Pot C.; Lalive P.H.; Yaldizli O.; Gobbi C.; Kappos L.; Kuhle J.; Saxer J.; Remonda L.; Boxheimer L.; Limberg M.; Scheerer I.; Orleth A.; Treppke F.; Beregi E.; Reinhardt J.; Fellner I.; Wurfel J.; Thoeni A.; Palatini A.; Pauli-Magnus C.; Fabbro T.; Roesler A.; Mechati S.; Chan A.; Salmen A.; Kaeser M.; Wagner F.; Verma R.; Di Marco M.; Haller S.; Lovblad K.-O.; Granziera C.; Hagmann P.; Maeder P.; Tschuor S.; Cianfoni A.; Weber J.. PLoS ONE. 2016.Tumefactive multiple sclerosis lesions under fingolimod: case series from an MS centre and review of phase 2 and 3 clinical trial data
Probstel, A. -K.; Radu, E. -W.; Mueller-Lenke, N.; Zhang-Auberson, L.; Bischof, D.; Merschhemke, M.; Kuhle, J.; Kappos, L.; Derfuss, T.; Decard, B.. Multiple sclerosis (Houndmills, Basingstoke, England). 2016.Validation of an automated lateral ventricle delineation algorithm (ALVIN) in multiple sclerosis
Ruberte, E.; Amann, M.; Naegelin, Y.; Penner, I. K.; Pardini, M.; Kuhle, J.; Derfuss, T.; Stippich, C.; Kappos, L.; Wuerfel, J.; Yaldizli, O.. Multiple sclerosis (Houndmills, Basingstoke, England). 2016.Chitinase 3-like 1: prognostic biomarker in clinically isolated syndromes.
Cantó E; Tintoré M; Villar LM; Costa C; Nurtdinov R; Álvarez-Cermeño JC; Arrambide G; Reverter F; Deisenhammer F; Hegen H; Khademi M; Olsson T; Tumani H; Rodríguez-Martín E; Piehl F; Bartos A; Zimova D; Kotoucova J; Kuhle J; Kappos L; García-Merino JA; Sánchez AJ; Saiz A; Blanco Y; Hintzen R; Jafari N; Brassat D; Lauda F; Roesler R; Rejdak K; Papuc E; de Andrés C; Rauch S; Khalil M; Enzinger C; Galimberti D; Scarpini E; Teunissen C; Sánchez A; Rovira A; Montalban X; Comabella M. Brain. 2015.Conversion from clinically isolated syndrome to multiple sclerosis: A large multicentre study.
Kuhle J; Disanto G; Dobson R; Adiutori R; Bianchi L; Topping J; Bestwick JP; Meier UC; Marta M; Dalla Costa G; Runia T; Evdoshenko E; Lazareva N; Thouvenot E; Iaffaldano P; Direnzo V; Khademi M; Piehl F; Comabella M; Sombekke M; Killestein J; Hegen H; Rauch S; D'Alfonso S; Alvarez-Cermeño JC; Kleinová P; Horáková D; Roesler R; Lauda F; Llufriu S; Avsar T; Uygunoglu U; Altintas A; Saip S; Menge T; Rajda C; Bergamaschi R; Moll N; Khalil M; Marignier R; Dujmovic I; Larsson H; Malmestrom C; Scarpini E; Fenoglio C; Wergeland S; Laroni A; Annibali V; Romano S; Martínez AD; Carra A; Salvetti M; Uccelli A; Torkildsen Ø; Myhr KM; Galimberti D; Rejdak K; Lycke J; Frederiksen JL; Drulovic J; Confavreux C; Brassat D; Enzinger C; Fuchs S; Bosca I; Pelletier J; Picard C; Colombo E; Franciotta D; Derfuss T; Lindberg R; Yaldizli Ö; Vécsei L; Kieseier BC; Hartung HP; Villoslada P; Siva A; Saiz A; Tumani H; Havrdová E; Villar LM; Leone M; Barizzone N; Deisenhammer F; Teunissen C; Montalban X; Tintoré M; Olsson T; Trojano M; Lehmann S; Castelnovo G; Lapin S; Hintzen R; Kappos L; Furlan R; Martinelli V; Comi G; Ramagopalan SV; Giovannoni G. Multiple sclerosis (Houndmills, Basingstoke, England). 2015.CSF neurofilament light chain reflects corticospinal tract degeneration in ALS.
Menke RA; Gray E; Lu CH; Kuhle J; Talbot K; Malaspina A; Turner MR. Annals of Clinical and Translational Neurology. 2015.Decision for intravenous thrombolysis in a young patient with acute vertical gaze palsy.
Papadopoulou A; Ahlhelm FJ; Lyrer P; Kuhle J. ACTA NEUROLOGICA BELGICA. 2015.Factors influencing long-term outcomes in relapsing-remitting multiple sclerosis: PRISMS-15.
Kappos L; Kuhle J; Multanen J; Kremenchutzky M; Verdun di Cantogno E; Cornelisse P; Lehr L; Casset-Semanaz F; Issard D; Uitdehaag BM. Journal of Neurology, Neurosurgery and Psychiatry. 2015.Fingolimod and CSF neurofilament light chain levels in relapsing-remitting multiple sclerosis.
Kuhle J; Disanto G; Lorscheider J; Stites T; Chen Y; Dahlke F; Francis G; Shrinivasan A; Radue EW; Giovannoni G; Kappos L. Neurology. 2015.Neurofilament light chain: A prognostic biomarker in amyotrophic lateral sclerosis.
Lu CH; Macdonald-Wallis C; Gray E; Pearce N; Petzold A; Norgren N; Giovannoni G; Fratta P; Sidle K; Fish M; Orrell R; Howard R; Talbot K; Greensmith L; Kuhle J; Turner MR; Malaspina A. Neurology. 2015.Plasma neurofilament heavy chain levels and disease progression in amyotrophic lateral sclerosis: insights from a longitudinal study.
Lu CH; Petzold A; Topping J; Allen K; Macdonald-Wallis C; Clarke J; Pearce N; Kuhle J; Giovannoni G; Fratta P; Sidle K; Fish M; Orrell R; Howard R; Greensmith L; Malaspina A. Journal of Neurology, Neurosurgery and Psychiatry. 2015.Quantified CSF antibody reactivity against myelin in multiple sclerosis.
Sun X; Bakhti M; Fitzner D; Schnaars M; Kruse N; Coskun Ü; Kremser C; Willecke K; Kappos L; Kuhle J; Simons M. Annals of Clinical and Translational Neurology. 2015.Serum neurofilament light chain is a biomarker of human spinal cord injury severity and outcome.
Kuhle J; Gaiottino J; Leppert D; Petzold A; Bestwick JP; Malaspina A; Lu CH; Dobson R; Disanto G; Norgren N; Nissim A; Kappos L; Hurlbert J; Yong VW; Giovannoni G; Casha S. Journal of Neurology, Neurosurgery and Psychiatry. 2015.Serum Neurofilament Light Chain Levels Are Associated with Clinical Characteristics and Outcome in Patients with Cervical Artery Dissection.
Traenka C; Disanto G; Seiffge DJ; Gensicke H; Hert L; Grond-Ginsbach C; Peters N; Regeniter A; Kloss M; De Marchis GM; Bonati LH; Lyrer PA; Kuhle J; Engelter ST. Cerebrovascular Diseases. 2015.Cholestenoic acids regulate motor neuron survival via liver X receptors.
Theofilopoulos S; Griffiths WJ; Crick PJ; Yang S; Meljon A; Ogundare M; Kitambi SS; Lockhart A; Tuschl K; Clayton PT; Morris AA; Martinez A; Reddy MA; Martinuzzi A; Bassi MT; Honda A; Mizuochi T; Kimura A; Nittono H; De Michele G; Carbone R; Criscuolo C; Yau JL; Seckl JR; Schüle R; Schöls L; Sailer AW; Kuhle J; Fraidakis MJ; Gustafsson JÅ; Steffensen KR; Björkhem I; Ernfors P; Sjövall J; Arenas E; Wang Y. Journal of Clinical Investigation. 2014.DNase hypersensitive sites and association with multiple sclerosis.
Disanto G; Kjetil Sandve G; Ricigliano VA; Pakpoor J; Berlanga-Taylor AJ; Handel AE; Kuhle J; Holden L; Watson CT; Giovannoni G; Handunnetthi L; Ramagopalan SV. Human Molecular Genetics. 2014.Guidelines for uniform reporting of body fluid biomarker studies in neurologic disorders.
Gnanapavan S; Hegen H; Khalil M; Hemmer B; Franciotta D; Hughes S; Hintzen R; Jeromin A; Havrdova E; Tumani H; Bertolotto A; Comabella M; Frederiksen J; Álvarez-Cermeño JC; Villar L; Galimberti D; Myhr KM; Dujmovic I; Fazekas F; Ionete C; Menge T; Kuhle J; Keir G; Deisenhammer F; Teunissen C; Giovannoni G. Neurology. 2014.Hypovitaminosis-D and EBV: no interdependence between two MS risk factors in a healthy young UK autumn cohort
Ramien, Caren; Pachnio, Annette; Sisay, Sofia; Begum, Jusnara; Leese, Alison; Disanto, Giulio; Kuhle, Jens; Giovannoni, Gavin; Rickinson, Alan; Ramagopalan, Sreeram V.; Moss, Paul; Meier, Ute-Christiane. Multiple sclerosis (Houndmills, Basingstoke, England). 2014.Immune reactivity to neurofilament proteins in the clinical staging of amyotrophic lateral sclerosis.
Puentes F; Topping J; Kuhle J; van der Star BJ; Douiri A; Giovannoni G; Baker D; Amor S; Malaspina A. Journal of Neurology, Neurosurgery and Psychiatry. 2014.Lesion-to-ventricle distance and other risk factors for the persistence of newly formed black holes in relapsing-remitting multiple sclerosis.
Papadopoulou A; Menegola M; Kuhle J; Ramagopalan SV; D'Souza M; Sprenger T; Radue EW; Kappos L; Yaldizli Ö. Multiple sclerosis (Houndmills, Basingstoke, England). 2014.MiR-126: a novel route for natalizumab action?
Meira M; Sievers C; Hoffmann F; Derfuss T; Kuhle J; Kappos L; Lindberg RL. Multiple sclerosis (Houndmills, Basingstoke, England). 2014.Multiple sclerosis registries in Europe - results of a systematic survey.
Flachenecker P; Buckow K; Pugliatti M; Kes VB; Battaglia MA; Boyko A; Confavreux C; Ellenberger D; Eskic D; Ford D; Friede T; Fuge J; Glaser A; Hillert J; Holloway E; Ioannidou E; Kappos L; Kasilingam E; Koch-Henriksen N; Kuhle J; Lepore V; Middleton R; Myhr KM; Orologas A; Otero S; Pitschnau-Michel D; Rienhoff O; Sastre-Garriga J; Schyns-Liharska T; Sutovic D; Thalheim C; Trojano M; Vlasov YV; Yaldizli O; EUReMS Consortium. Multiple sclerosis (Houndmills, Basingstoke, England). 2014.Neurofilament light antibodies in serum reflect response to natalizumab treatment in multiple sclerosis.
Amor S; van der Star BJ; Bosca I; Raffel J; Gnanapavan S; Watchorn J; Kuhle J; Giovannoni G; Baker D; Malaspina A; Puentes F. Multiple sclerosis (Houndmills, Basingstoke, England). 2014.The refinement of genetic predictors of multiple sclerosis.
Disanto G; Dobson R; Pakpoor J; Elangovan RI; Adiutori R; Kuhle J; Giovannoni G. PLoS ONE. 2014.The relationship between total and regional corpus callosum atrophy, cognitive impairment and fatigue in multiple sclerosis patients.
Yaldizli Ö; Penner IK; Frontzek K; Naegelin Y; Amann M; Papadopoulou A; Sprenger T; Kuhle J; Calabrese P; Radü EW; Kappos L; Gass A. Multiple sclerosis (Houndmills, Basingstoke, England). 2014.Unraveling natalizumab effects on deregulated miR-17 expression in CD4+ T cells of patients with relapsing-remitting multiple sclerosis.
Meira M; Sievers C; Hoffmann F; Rasenack M; Kuhle J; Derfuss T; Kappos L; Lindberg RL. Journal of Immunology Research. 2014.A comparative study of CSF neurofilament light and heavy chain protein in MS.
Kuhle J; Plattner K; Bestwick JP; Lindberg RL; Ramagopalan SV; Norgren N; Nissim A; Malaspina A; Leppert D; Giovannoni G; Kappos L. Multiple sclerosis (Houndmills, Basingstoke, England). 2013.Balance control in multiple sclerosis: correlations of trunk sway during stance and gait tests with disease severity.
Corporaal SH; Gensicke H; Kuhle J; Kappos L; Allum JH; Yaldizli Ö. Gait and Posture. 2013.Cerebrospinal fluid parameters of B cell-related activity in patients with active disease during natalizumab therapy.
Harrer A; Tumani H; Niendorf S; Lauda F; Geis C; Weishaupt A; Kleinschnitz C; Rauer S; Kuhle J; Stangel M; Weber F; Uhr M; Linnebank M; Wildemann B; Jarius S; Guger M; Ayzenberg I; Chan A; Zettl U; Wiendl H; Pilz G; Hitzl W; Weber JR; Kraus J. Multiple sclerosis (Houndmills, Basingstoke, England). 2013.Consensus definitions and application guidelines for control groups in cerebrospinal fluid biomarker studies in multiple sclerosis.
Teunissen C; Menge T; Altintas A; Álvarez-Cermeño JC; Bertolotto A; Berven FS; Brundin L; Comabella M; Degn M; Deisenhammer F; Fazekas F; Franciotta D; Frederiksen JL; Galimberti D; Gnanapavan S; Hegen H; Hemmer B; Hintzen R; Hughes S; Iacobaeus E; Kroksveen AC; Kuhle J; Richert J; Tumani H; Villar LM; Drulovic J; Dujmovic I; Khalil M; Bartos A. Multiple sclerosis (Houndmills, Basingstoke, England). 2013.Increased neurofilament light chain blood levels in neurodegenerative neurological diseases.
Gaiottino J; Norgren N; Dobson R; Topping J; Nissim A; Malaspina A; Bestwick JP; Monsch AU; Regeniter A; Lindberg RL; Kappos L; Leppert D; Petzold A; Giovannoni G; Kuhle J. PLoS ONE. 2013.Natalizumab therapy for multiple sclerosis.
Derfuss T; Kuhle J; Lindberg R; Kappos L. Seminars in Neurology. 2013.Neurofilament light and heavy subunits compared as therapeutic biomarkers in multiple sclerosis.
Kuhle J; Malmeström C; Axelsson M; Plattner K; Yaldizli O; Derfuss T; Giovannoni G; Kappos L; Lycke J. Acta neurologica Scandinavica. 2013.Neurologist in training
Yaldizli,Ö; Kuhle,J; Derfuss,T; Sprenger,T; Kappos,L. . 2013.Neurologist-in-training: Multiple sclerosis
Yaldizli O.; Kuhle J.; Derfuss T.; Sprenger T.; Kappos L.. Schweizer Archiv fur Neurologie und Psychiatrie. 2013.T-cell response against varicella-zoster virus in fingolimod-treated MS patients.
Ricklin,Meret E; Lorscheider,Johannes; Waschbisch,Anne; Paroz,Cecile; Mehta,Satish K; Pierson,Duane L; Kuhle,Jens; Fischer-Barnicol,Bettina; Sprenger,Till; Lindberg,Raija L P; Kappos,Ludwig; Derfuss,Tobias. Neurology. 2013.The effect of vitamin D-related interventions on multiple sclerosis relapses: a meta-analysis.
James E; Dobson R; Kuhle J; Baker D; Giovannoni G; Ramagopalan SV. Multiple sclerosis (Houndmills, Basingstoke, England). 2013.Biomarkers of dementia: comparison of electrochemiluminescence results and reference ranges with conventional ELISA.
Regeniter A; Kuhle J; Baumann T; Sollberger M; Herdener M; Kunze U; Camuso MC; Monsch AU. Methods. 2012.Monoclonal antibodies and recombinant immunoglobulins for the treatment of multiple sclerosis.
Gensicke H; Leppert D; Yaldizli Ö; Lindberg RL; Mehling M; Kappos L; Kuhle J. CNS drugs. 2012.Neurofilament heavy chain and heat shock protein 70 as markers of seizure-related brain injury.
Rejdak K; Kuhle J; Rüegg S; Lindberg RL; Petzold A; Sulejczak D; Papuc E; Rejdak R; Stelmasiak Z; Grieb P. Epilepsia. 2012.Pathology of immune reconstitution inflammatory syndrome in multiple sclerosis with natalizumab-associated progressive multifocal leukoencephalopathy.
Metz I; Radue EW; Oterino A; Kümpfel T; Wiendl H; Schippling S; Kuhle J; Sahraian MA; Gray F; Jakl V; Häusler D; Brück W. Acta neuropathologica. 2012.Placental α-microglobulin-1 to detect uncertain rupture of membranes in a European cohort of pregnancies.
Birkenmaier,Ariane; Ries,Jean-Jacques; Kuhle,Jens; Bürki,Nicole; Lapaire,Olav; Hösli,Irene. Archives of Gynecology and Obstetrics. 2012.Screening for balance disorders in mildly affected multiple sclerosis patients.
Fanchamps MH; Gensicke H; Kuhle J; Kappos L; Allum JH; Yaldizli O. Journal of Neurology. 2012.Antigen-specific adaptive immune responses in fingolimod-treated multiple sclerosis patients.
Mehling M; Hilbert P; Fritz S; Durovic B; Eichin D; Gasser O; Kuhle J; Klimkait T; Lindberg RL; Kappos L; Hess C. Annals of Neurology. 2011.Consensus Guidelines for CSF and Blood Biobanking for CNS Biomarker Studies.
Teunissen CE; Tumani H; Bennett JL; Berven FS; Brundin L; Comabella M; Franciotta D; Federiksen JL; Fleming JO; Furlan R; Hintzen RQ; Hughes SG; Jimenez CR; Johnson MH; Killestein J; Krasulova E; Kuhle J; Magnone MC; Petzold A; Rajda C; Rejdak K; Schmidt HK; van Pesch V; Waubant E; Wolf C; Deisenhammer F; Giovannoni G; Hemmer B. . 2011.Management and outcome of CSF-JC virus PCR-negative PML in a natalizumab-treated patient with MS.
Kuhle J; Gosert R; Bühler R; Derfuss T; Sutter R; Yaldizli O; Radue EW; Ryschkewitsch C; Major EO; Kappos L; Frank S; Hirsch HH. Neurology. 2011.Neurofilament heavy chain in CSF correlates with relapses and disability in multiple sclerosis.
Kuhle J; Leppert D; Petzold A; Regeniter A; Schindler C; Mehling M; Anthony DC; Kappos L; Lindberg RL. Neurology. 2011.Neurologist-in-training
Yaldizli O.; Kuhle J.; Derfuss T.; Sprenger T.; Kappos L.. Schweizer Archiv fur Neurologie und Psychiatrie. 2011.Soluble beta-amyloid precursor protein is related to disease progression in amyotrophic lateral sclerosis.
Steinacker P; Fang L; Kuhle J; Petzold A; Tumani H; Ludolph AC; Otto M; Brettschneider J. PLoS ONE. 2011.What makes a prognostic biomarker in CNS diseases: strategies for targeted biomarker discovery? Part 1: acute and monophasic diseases.
Kuhle J; Petzold A. Expert opinion on medical diagnostics. 2011.What makes a prognostic biomarker in CNS diseases: strategies for targeted biomarker discovery? Part 2: chronic progressive and relapsing disease.
Kuhle J; Petzold A. Expert opinion on medical diagnostics. 2011.A highly sensitive electrochemiluminescence immunoassay for the neurofilament heavy chain protein.
Kuhle J; Regeniter A; Leppert D; Mehling M; Kappos L; Lindberg RL; Petzold A. Journal of Neuroimmunology. 2010.Altered expression of miR-17-5p in CD4+ lymphocytes of relapsing-remitting multiple sclerosis patients.
Lindberg RL; Hoffmann F; Mehling M; Kuhle J; Kappos L. European journal of immunology. 2010.CSF-tau and CSF-Abeta(1-42) in posterior cortical atrophy.
Baumann TP; Duyar H; Sollberger M; Kuhle J; Regeniter A; Gomez-Mancilla B; Schmidtke K; Monsch AU. Dementia and geriatric cognitive disorders. 2010.Evidence for acute neurotoxicity after chemotherapy.
Petzold A; Mondria T; Kuhle J; Rocca MA; Cornelissen J; te Boekhorst P; Lowenberg B; Giovannoni G; Filippi M; Kappos L; Hintzen R. Annals of Neurology. 2010.Genetik und molekulare Untersuchungen
Lindberg,R; Nägelin,Y; Kuhle,J; Kappos,L. . 2010.Neurofilament ELISA validation.
Petzold A; Altintas A; Andreoni L; Bartos A; Berthele A; Blankenstein MA; Buee L; Castellazzi M; Cepok S; Comabella M; Constantinescu CS; Deisenhammer F; Deniz G; Erten G; Espiño M; Fainardi E; Franciotta D; Freedman MS; Giedraitis V; Gilhus NE; Giovannoni G; Glabinski A; Grieb P; Hartung HP; Hemmer B; Herukka SK; Hintzen R; Ingelsson M; Jackson S; Jacobsen S; Jafari N; Jalosinski M; Jarius S; Kapaki E; Kieseier BC; Koel-Simmelink MJ; Kornhuber J; Kuhle J; Kurzepa J; Lalive PH; Lannfelt L; Lehmensiek V; Lewczuk P; Livrea P; Marnetto F; Martino D; Menge T; Norgren N; Papuć E; Paraskevas GP; Pirttilä T; Rajda C; Rejdak K; Ricny J; Ripova D; Rosengren L; Ruggieri M; Schraen S; Shaw G; Sindic C; Siva A; Stigbrand T; Stonebridge I; Topcular B; Trojano M; Tumani H; Twaalfhoven HA; Vécsei L; Van Pesch V; Vanderstichele H; Vedeler C; Verbeek MM; Villar LM; Weissert R; Wildemann B; Yang C; Yao K; Teunissen CE. Journal of Immunological Methods. 2010.Phase II study of oral fingolimod (FTY720) in multiple sclerosis: 3-year results.
Comi G; O'Connor P; Montalban X; Antel J; Radue EW; Karlsson G; Pohlmann H; Aradhye S; Kappos L; FTY720D2201 Study Group. Multiple sclerosis (Houndmills, Basingstoke, England). 2010.Short commentary on 'a consensus protocol for the standardization of cerebrospinal fluid collection and biobanking'.
Teunissen CE; Tumani HT; Bennett JL; Berven FS; Brundin L; Comabella M; Franciotta D; Federiksen JL; Fleming JO; Furlan R; Hintzen RQ; Hughes SG; Johnson MH; Krasulova E; Kuhle J; Magnone MC; Petzold A; Rajda C; Rejdak K; Schmidt HK; van Pesch V; Waubant E; Wolf C; Hemmer B; Deisenhammer F; Giovannoni G. Multiple sclerosis (Houndmills, Basingstoke, England). 2010.Th17 central memory T cells are reduced by FTY720 in patients with multiple sclerosis.
Mehling M; Lindberg R; Raulf F; Kuhle J; Hess C; Kappos L; Brinkmann V. Neurology. 2010.A consensus protocol for the standardization of cerebrospinal fluid collection and biobanking.
Teunissen CE; Petzold A; Bennett JL; Berven FS; Brundin L; Comabella M; Franciotta D; Frederiksen JL; Fleming JO; Furlan R; Hintzen RQ; Hughes SG; Johnson MH; Krasulova E; Kuhle J; Magnone MC; Rajda C; Rejdak K; Schmidt HK; van Pesch V; Waubant E; Wolf C; Giovannoni G; Hemmer B; Tumani H; Deisenhammer F. Neurology. 2009.Age-dependent B cell autoimmunity to a myelin surface antigen in pediatric multiple sclerosis.
McLaughlin KA; Chitnis T; Newcombe J; Franz B; Kennedy J; McArdel S; Kuhle J; Kappos L; Rostasy K; Pohl D; Gagne D; Ness JM; Tenembaum S; O'Connor KC; Viglietta V; Wong SJ; Tavakoli NP; de Seze J; Idrissova Z; Khoury SJ; Bar-Or A; Hafler DA; Banwell B; Wucherpfennig KW. Journal of Immunology. 2009.A modern approach to CSF analysis: pathophysiology, clinical application, proof of concept and laboratory reporting.
Regeniter A; Kuhle J; Mehling M; Möller H; Wurster U; Freidank H; Siede WH. Clinical neurology and neurosurgery. 2009.Cerebrospinal fluid biomarkers in multiple sclerosis
Tumani, Hayrettin; Hartung, Hans-Peter; Hemmer, Bernhard; Teunissen, Charlotte; Deisenhammer, Florian; Giovannoni, Gavin; Zettl, Uwe K.. Neurobiology of disease. 2009.Increased levels of inflammatory chemokines in amyotrophic lateral sclerosis.
Kuhle J; Lindberg RL; Regeniter A; Mehling M; Steck AJ; Kappos L; Czaplinski A. European Journal of Neurology. 2009.Oral fingolimod (FTY720) in multiple sclerosis: two-year results of a phase II extension study.
O'Connor P; Comi G; Montalban X; Antel J; Radue EW; de Vera A; Pohlmann H; Kappos L; FTY720 D2201 Study Group. Neurology. 2009.10 most commonly asked questions about cerebrospinal fluid characteristics in demyelinating disorders of the central nervous system.
Mehling M; Kuhle J; Regeniter A. NEUROLOGIST. 2008.Adaptation of antiretroviral therapy in human immunodeficiency virus infection with central nervous system involvement.
Mehling M; Drechsler H; Kuhle J; Hardmeier M; Doerries R; Ruegg S; Gass A. Journal of neurovirology. 2008.Efficacy and safety of oral fumarate in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb study.
Kappos L; Gold R; Miller DH; Macmanus DG; Havrdova E; Limmroth V; Polman CH; Schmierer K; Yousry TA; Yang M; Eraksoy M; Meluzinova E; Rektor I; Dawson KT; Sandrock AW; O'Neill GN; BG-12 Phase IIb Study Investigators. The Lancet. 2008.FTY720 therapy exerts differential effects on T cell subsets in multiple sclerosis
Mehling M.; Brinkmann V.; Antel J.; Bar-Or A.; Goebels N.; Vedrine C.; Kristofic C.; Kuhle J.; Lindberg R.L.P.; Kappos L.. Neurology. 2008.Intrathecal anti-alphaB-crystallin IgG antibody responses: potential inflammatory markers in Guillain-Barré syndrome.
Wanschitz J; Ehling R; Löscher WN; Künz B; Deisenhammer F; Kuhle J; Budka H; Reindl M; Berger T. Journal of Neurology. 2008.Liquordiagnostik der Multiplen Sklerose - Diagnose und Differentialdiagnose.
Schlaeger,R; Mehling,M; Gass,A; Kuhle,J. . 2008.Natalizumab alters transcriptional expression profiles of blood cell subpopulations of multiple sclerosis patients.
Lindberg RL; Achtnichts L; Hoffmann F; Kuhle J; Kappos L. Journal of Neuroimmunology. 2008.Übersicht und Empfehlungen der SULM zur Liquordiagnostik.
Huber,A; Kuhle,J; Goebels,N; Risch,M; Zweifel,R; Regeniter,A. . 2008.Antimyelin antibodies in clinically isolated syndromes correlate with inflammation in MRI and CSF.
Kuhle J; Lindberg RL; Regeniter A; Mehling M; Hoffmann F; Reindl M; Berger T; Radue EW; Leppert D; Kappos L. Journal of Neurology. 2007.Lack of association between antimyelin antibodies and progression to multiple sclerosis.
Kuhle J; Pohl C; Mehling M; Edan G; Freedman MS; Hartung HP; Polman CH; Miller DH; Montalban X; Barkhof F; Bauer L; Dahms S; Lindberg R; Kappos L; Sandbrink R. New England Journal of Medicine. 2007.Lack of association between antimyelin antibodies and progression to multiple sclerosis - Reply
Kappos, Ludwig; Kuhle, Jens; Sandbrink, Rupert. New England Journal of Medicine. 2007.Moderne Liquordiagnostik. Eine Übersicht.
Kuhle,J; Mehling,M; Regeniter,A. . 2007.Serum-Antikörper geben doch keinen Hinweis auf MS-Risiko.
Kuhle,J. . 2007.Severe post-EBV encephalopathy associated with myelin oligodendrocyte glycoprotein-specific immune response.
Jilek S; Kuhle J; Meylan P; Reichhart MD; Pantaleo G; Du Pasquier RA. Journal of Neuroimmunology. 2007.Oral fingolimod (FTY720) for relapsing multiple sclerosis.
Kappos L; Antel J; Comi G; Montalban X; O'Connor P; Polman CH; Haas T; Korn AA; Karlsson G; Radue EW; FTY720 D2201 Study Group. New England Journal of Medicine. 2006.Genomics and proteomics: role in the management of multiple sclerosis.
Kappos L; Achtnichts L; Dahlke F; Kuhle J; Naegelin Y; Sandbrink R; Lindberg RL. Journal of Neurology. 2005.Alternatives to current disease-modifying treatment in MS: what do we need and what can we expect in the future?
Kappos L; Kuhle J; Gass A; Achtnichts L; Radue EW. Journal of Neurology. 2004.Clinically Isolated Syndrome (CIS) bei Multipler Sklerose: Geben Myelin-Antikörper Aufschluss über die Prognose?
Kuhle,J; Gobbi,C. . 2004.High immunogenicity of intracellular myelin oligodendrocyte glycoprotein epitopes.
Weissert R; Kuhle J; de Graaf KL; Wienhold W; Herrmann MM; Müller C; Forsthuber TG; Wiesmüller KH; Melms A. Journal of Immunology. 2002.